id	sid	tid	token	lemma	pos
cord-302756-343y63e5	1	1	key	key	JJ
cord-302756-343y63e5	1	2	:	:	:
cord-302756-343y63e5	1	3	cord-302756	cord-302756	NNP
cord-302756-343y63e5	1	4	-	-	HYPH
cord-302756-343y63e5	1	5	343y63e5	343y63e5	CD
cord-302756-343y63e5	1	6	authors	author	NNS
cord-302756-343y63e5	1	7	:	:	:
cord-302756-343y63e5	1	8	Thachil	Thachil	NNP
cord-302756-343y63e5	1	9	,	,	,
cord-302756-343y63e5	1	10	J	J	NNP
cord-302756-343y63e5	1	11	;	;	:
cord-302756-343y63e5	1	12	Agarwal	Agarwal	NNP
cord-302756-343y63e5	1	13	,	,	,
cord-302756-343y63e5	1	14	S.	S.	NNP
cord-302756-343y63e5	1	15	title	title	NN
cord-302756-343y63e5	1	16	:	:	:
cord-302756-343y63e5	1	17	Understanding	understand	VBG
cord-302756-343y63e5	1	18	the	the	DT
cord-302756-343y63e5	1	19	COVID‐19	COVID‐19	NNP
cord-302756-343y63e5	1	20	coagulopathy	coagulopathy	NN
cord-302756-343y63e5	1	21	spectrum	spectrum	NN
cord-302756-343y63e5	1	22	date	date	NN
cord-302756-343y63e5	1	23	:	:	:
cord-302756-343y63e5	1	24	2020	2020	CD
cord-302756-343y63e5	1	25	-	-	HYPH
cord-302756-343y63e5	1	26	05	05	CD
cord-302756-343y63e5	1	27	-	-	SYM
cord-302756-343y63e5	1	28	21	21	CD
cord-302756-343y63e5	1	29	journal	journal	NN
cord-302756-343y63e5	1	30	:	:	:
cord-302756-343y63e5	2	1	Anaesthesia	anaesthesia	NN
cord-302756-343y63e5	2	2	DOI	DOI	NNP
cord-302756-343y63e5	2	3	:	:	:
cord-302756-343y63e5	3	1	10.1111	10.1111	CD
cord-302756-343y63e5	3	2	/	/	SYM
cord-302756-343y63e5	3	3	anae.15141	anae.15141	NNP
cord-302756-343y63e5	3	4	sha	sha	NNP
cord-302756-343y63e5	3	5	:	:	:
cord-302756-343y63e5	4	1	8c23b2b5075114118d470e0912e09e0ff3fccb0c	8c23b2b5075114118d470e0912e09e0ff3fccb0c	CD
cord-302756-343y63e5	4	2	doc_id	doc_id	CD
cord-302756-343y63e5	4	3	:	:	:
cord-302756-343y63e5	4	4	302756	302756	CD
cord-302756-343y63e5	4	5	cord_uid	cord_uid	NNS
cord-302756-343y63e5	4	6	:	:	:
cord-302756-343y63e5	4	7	343y63e5	343y63e5	CD
cord-302756-343y63e5	5	1	The	the	DT
cord-302756-343y63e5	5	2	SARS‐Cov‐2	SARS‐Cov‐2	NNS
cord-302756-343y63e5	5	3	(	(	-LRB-
cord-302756-343y63e5	5	4	COVID‐19	covid‐19	NN
cord-302756-343y63e5	5	5	)	)	-RRB-
cord-302756-343y63e5	5	6	pandemic	pandemic	NN
cord-302756-343y63e5	5	7	has	have	VBZ
cord-302756-343y63e5	5	8	already	already	RB
cord-302756-343y63e5	5	9	claimed	claim	VBN
cord-302756-343y63e5	5	10	over	over	IN
cord-302756-343y63e5	5	11	200,000	200,000	CD
cord-302756-343y63e5	5	12	lives	life	NNS
cord-302756-343y63e5	5	13	.	.	.
cord-302756-343y63e5	6	1	Quite	quite	RB
cord-302756-343y63e5	6	2	early	early	RB
cord-302756-343y63e5	6	3	on	on	RB
cord-302756-343y63e5	6	4	in	in	IN
cord-302756-343y63e5	6	5	this	this	DT
cord-302756-343y63e5	6	6	pandemic	pandemic	NN
cord-302756-343y63e5	6	7	,	,	,
cord-302756-343y63e5	6	8	it	-PRON-	PRP
cord-302756-343y63e5	6	9	was	be	VBD
cord-302756-343y63e5	6	10	recognised	recognise	VBN
cord-302756-343y63e5	6	11	that	that	IN
cord-302756-343y63e5	6	12	the	the	DT
cord-302756-343y63e5	6	13	virus	virus	NN
cord-302756-343y63e5	6	14	triggers	trigger	VBZ
cord-302756-343y63e5	6	15	the	the	DT
cord-302756-343y63e5	6	16	immune	immune	JJ
cord-302756-343y63e5	6	17	system	system	NN
cord-302756-343y63e5	6	18	leading	lead	VBG
cord-302756-343y63e5	6	19	to	to	IN
cord-302756-343y63e5	6	20	a	a	DT
cord-302756-343y63e5	6	21	cytokine	cytokine	NN
cord-302756-343y63e5	6	22	storm	storm	NN
cord-302756-343y63e5	6	23	in	in	IN
cord-302756-343y63e5	6	24	some	some	DT
cord-302756-343y63e5	6	25	severely	severely	RB
cord-302756-343y63e5	6	26	ill	ill	JJ
cord-302756-343y63e5	6	27	patients	patient	NNS
cord-302756-343y63e5	6	28	[	[	-LRB-
cord-302756-343y63e5	6	29	1	1	CD
cord-302756-343y63e5	6	30	]	]	-RRB-
cord-302756-343y63e5	6	31	.	.	.
cord-302756-343y63e5	7	1	This	this	DT
cord-302756-343y63e5	7	2	hyper‐responsiveness	hyper‐responsiveness	NN
cord-302756-343y63e5	7	3	has	have	VBZ
cord-302756-343y63e5	7	4	been	be	VBN
cord-302756-343y63e5	7	5	suggested	suggest	VBN
cord-302756-343y63e5	7	6	to	to	TO
cord-302756-343y63e5	7	7	be	be	VB
cord-302756-343y63e5	7	8	the	the	DT
cord-302756-343y63e5	7	9	predominant	predominant	JJ
cord-302756-343y63e5	7	10	aetiology	aetiology	NN
cord-302756-343y63e5	7	11	for	for	IN
cord-302756-343y63e5	7	12	clinical	clinical	JJ
cord-302756-343y63e5	7	13	deterioration	deterioration	NN
cord-302756-343y63e5	7	14	and	and	CC
cord-302756-343y63e5	7	15	mortality	mortality	NN
cord-302756-343y63e5	7	16	in	in	IN
cord-302756-343y63e5	7	17	patients	patient	NNS
cord-302756-343y63e5	7	18	with	with	IN
cord-302756-343y63e5	7	19	this	this	DT
cord-302756-343y63e5	7	20	infection	infection	NN
cord-302756-343y63e5	7	21	[	[	-LRB-
cord-302756-343y63e5	7	22	2	2	CD
cord-302756-343y63e5	7	23	]	]	-RRB-
cord-302756-343y63e5	7	24	.	.	.
cord-302756-343y63e5	8	1	More	more	RBR
cord-302756-343y63e5	8	2	recently	recently	RB
cord-302756-343y63e5	8	3	,	,	,
cord-302756-343y63e5	8	4	there	there	EX
cord-302756-343y63e5	8	5	have	have	VBP
cord-302756-343y63e5	8	6	been	be	VBN
cord-302756-343y63e5	8	7	several	several	JJ
cord-302756-343y63e5	8	8	reports	report	NNS
cord-302756-343y63e5	8	9	of	of	IN
cord-302756-343y63e5	8	10	increased	increase	VBN
cord-302756-343y63e5	8	11	thrombotic	thrombotic	JJ
cord-302756-343y63e5	8	12	events	event	NNS
cord-302756-343y63e5	8	13	in	in	IN
cord-302756-343y63e5	8	14	these	these	DT
cord-302756-343y63e5	8	15	patients	patient	NNS
cord-302756-343y63e5	8	16	[	[	-LRB-
cord-302756-343y63e5	8	17	3‐6	3‐6	CD
cord-302756-343y63e5	8	18	]	]	-RRB-
cord-302756-343y63e5	8	19	.	.	.
cord-302756-343y63e5	9	1	From	from	IN
cord-302756-343y63e5	9	2	a	a	DT
cord-302756-343y63e5	9	3	laboratory	laboratory	NN
cord-302756-343y63e5	9	4	perspective	perspective	NN
cord-302756-343y63e5	9	5	,	,	,
cord-302756-343y63e5	9	6	this	this	DT
cord-302756-343y63e5	9	7	hypercoagulability	hypercoagulability	NN
cord-302756-343y63e5	9	8	is	be	VBZ
cord-302756-343y63e5	9	9	reflected	reflect	VBN
cord-302756-343y63e5	9	10	in	in	IN
cord-302756-343y63e5	9	11	the	the	DT
cord-302756-343y63e5	9	12	marked	marked	JJ
cord-302756-343y63e5	9	13	elevation	elevation	NN
cord-302756-343y63e5	9	14	of	of	IN
cord-302756-343y63e5	9	15	the	the	DT
cord-302756-343y63e5	9	16	fibrinolytic	fibrinolytic	JJ
cord-302756-343y63e5	9	17	marker	marker	NN
cord-302756-343y63e5	9	18	,	,	,
cord-302756-343y63e5	9	19	D‐dimer	D‐dimer	NNP
cord-302756-343y63e5	9	20	,	,	,
cord-302756-343y63e5	9	21	in	in	IN
cord-302756-343y63e5	9	22	almost	almost	RB
cord-302756-343y63e5	9	23	all	all	DT
cord-302756-343y63e5	9	24	hospitalised	hospitalise	VBN
cord-302756-343y63e5	9	25	COVID‐19	COVID‐19	NNP
cord-302756-343y63e5	9	26	patients	patient	NNS
cord-302756-343y63e5	9	27	[	[	-LRB-
cord-302756-343y63e5	9	28	7	7	CD
cord-302756-343y63e5	9	29	]	]	-RRB-
cord-302756-343y63e5	9	30	.	.	.
cord-302756-343y63e5	10	1	We	-PRON-	PRP
cord-302756-343y63e5	10	2	must	must	MD
cord-302756-343y63e5	10	3	,	,	,
cord-302756-343y63e5	10	4	therefore	therefore	RB
cord-302756-343y63e5	10	5	,	,	,
cord-302756-343y63e5	10	6	ask	ask	VB
cord-302756-343y63e5	10	7	ourselves	-PRON-	PRP
cord-302756-343y63e5	10	8	what	what	WP
cord-302756-343y63e5	10	9	is	be	VBZ
cord-302756-343y63e5	10	10	the	the	DT
cord-302756-343y63e5	10	11	link	link	NN
cord-302756-343y63e5	10	12	between	between	IN
cord-302756-343y63e5	10	13	the	the	DT
cord-302756-343y63e5	10	14	extremes	extreme	NNS
cord-302756-343y63e5	10	15	of	of	IN
cord-302756-343y63e5	10	16	the	the	DT
cord-302756-343y63e5	10	17	immune	immune	JJ
cord-302756-343y63e5	10	18	system	system	NN
cord-302756-343y63e5	10	19	,	,	,
cord-302756-343y63e5	10	20	presenting	present	VBG
cord-302756-343y63e5	10	21	as	as	IN
cord-302756-343y63e5	10	22	cytokine	cytokine	NN
cord-302756-343y63e5	10	23	storm	storm	NN
cord-302756-343y63e5	10	24	,	,	,
cord-302756-343y63e5	10	25	and	and	CC
cord-302756-343y63e5	10	26	the	the	DT
cord-302756-343y63e5	10	27	extremes	extreme	NNS
cord-302756-343y63e5	10	28	of	of	IN
cord-302756-343y63e5	10	29	coagulation	coagulation	NN
cord-302756-343y63e5	10	30	,	,	,
cord-302756-343y63e5	10	31	presenting	present	VBG
cord-302756-343y63e5	10	32	as	as	IN
cord-302756-343y63e5	10	33	arterial	arterial	JJ
cord-302756-343y63e5	10	34	and	and	CC
cord-302756-343y63e5	10	35	venous	venous	JJ
cord-302756-343y63e5	10	36	thromboembolism	thromboembolism	NN
cord-302756-343y63e5	10	37	?	?	.
cord-302756-343y63e5	11	1	This	this	DT
cord-302756-343y63e5	11	2	article	article	NN
cord-302756-343y63e5	11	3	is	be	VBZ
cord-302756-343y63e5	11	4	protected	protect	VBN
cord-302756-343y63e5	11	5	by	by	IN
cord-302756-343y63e5	11	6	copyright	copyright	NN
cord-302756-343y63e5	11	7	.	.	.
cord-302756-343y63e5	12	1	All	all	DT
cord-302756-343y63e5	12	2	rights	right	NNS
cord-302756-343y63e5	12	3	reserved	reserve	VBN
cord-302756-343y63e5	13	1	The	the	DT
cord-302756-343y63e5	13	2	SARS	SARS	NNP
cord-302756-343y63e5	13	3	-	-	HYPH
cord-302756-343y63e5	13	4	Cov-2	Cov-2	NNP
cord-302756-343y63e5	13	5	(	(	-LRB-
cord-302756-343y63e5	13	6	COVID-19	covid-19	VB
cord-302756-343y63e5	13	7	)	)	-RRB-
cord-302756-343y63e5	13	8	pandemic	pandemic	NN
cord-302756-343y63e5	13	9	has	have	VBZ
cord-302756-343y63e5	13	10	already	already	RB
cord-302756-343y63e5	13	11	claimed	claim	VBN
cord-302756-343y63e5	13	12	over	over	IN
cord-302756-343y63e5	13	13	200,000	200,000	CD
cord-302756-343y63e5	13	14	lives	life	NNS
cord-302756-343y63e5	13	15	.	.	.
cord-302756-343y63e5	14	1	Quite	quite	RB
cord-302756-343y63e5	14	2	early	early	RB
cord-302756-343y63e5	14	3	on	on	RB
cord-302756-343y63e5	14	4	in	in	IN
cord-302756-343y63e5	14	5	this	this	DT
cord-302756-343y63e5	14	6	pandemic	pandemic	NN
cord-302756-343y63e5	14	7	,	,	,
cord-302756-343y63e5	14	8	it	-PRON-	PRP
cord-302756-343y63e5	14	9	was	be	VBD
cord-302756-343y63e5	14	10	recognised	recognise	VBN
cord-302756-343y63e5	14	11	that	that	IN
cord-302756-343y63e5	14	12	the	the	DT
cord-302756-343y63e5	14	13	virus	virus	NN
cord-302756-343y63e5	14	14	triggers	trigger	VBZ
cord-302756-343y63e5	14	15	the	the	DT
cord-302756-343y63e5	14	16	immune	immune	JJ
cord-302756-343y63e5	14	17	system	system	NN
cord-302756-343y63e5	14	18	leading	lead	VBG
cord-302756-343y63e5	14	19	to	to	IN
cord-302756-343y63e5	14	20	a	a	DT
cord-302756-343y63e5	14	21	cytokine	cytokine	NN
cord-302756-343y63e5	14	22	storm	storm	NN
cord-302756-343y63e5	14	23	in	in	IN
cord-302756-343y63e5	14	24	some	some	DT
cord-302756-343y63e5	14	25	severely	severely	RB
cord-302756-343y63e5	14	26	ill	ill	JJ
cord-302756-343y63e5	14	27	patients	patient	NNS
cord-302756-343y63e5	14	28	[	[	-LRB-
cord-302756-343y63e5	14	29	1	1	CD
cord-302756-343y63e5	14	30	]	]	-RRB-
cord-302756-343y63e5	14	31	.	.	.
cord-302756-343y63e5	15	1	This	this	DT
cord-302756-343y63e5	15	2	hyper	hyper	JJ
cord-302756-343y63e5	15	3	-	-	NN
cord-302756-343y63e5	15	4	responsiveness	responsiveness	NN
cord-302756-343y63e5	15	5	has	have	VBZ
cord-302756-343y63e5	15	6	been	be	VBN
cord-302756-343y63e5	15	7	suggested	suggest	VBN
cord-302756-343y63e5	15	8	to	to	TO
cord-302756-343y63e5	15	9	be	be	VB
cord-302756-343y63e5	15	10	the	the	DT
cord-302756-343y63e5	15	11	predominant	predominant	JJ
cord-302756-343y63e5	15	12	aetiology	aetiology	NN
cord-302756-343y63e5	15	13	for	for	IN
cord-302756-343y63e5	15	14	clinical	clinical	JJ
cord-302756-343y63e5	15	15	deterioration	deterioration	NN
cord-302756-343y63e5	15	16	and	and	CC
cord-302756-343y63e5	15	17	mortality	mortality	NN
cord-302756-343y63e5	15	18	in	in	IN
cord-302756-343y63e5	15	19	patients	patient	NNS
cord-302756-343y63e5	15	20	with	with	IN
cord-302756-343y63e5	15	21	this	this	DT
cord-302756-343y63e5	15	22	infection	infection	NN
cord-302756-343y63e5	15	23	[	[	-LRB-
cord-302756-343y63e5	15	24	2	2	CD
cord-302756-343y63e5	15	25	]	]	-RRB-
cord-302756-343y63e5	15	26	.	.	.
cord-302756-343y63e5	16	1	More	more	RBR
cord-302756-343y63e5	16	2	recently	recently	RB
cord-302756-343y63e5	16	3	,	,	,
cord-302756-343y63e5	16	4	there	there	EX
cord-302756-343y63e5	16	5	have	have	VBP
cord-302756-343y63e5	16	6	been	be	VBN
cord-302756-343y63e5	16	7	several	several	JJ
cord-302756-343y63e5	16	8	reports	report	NNS
cord-302756-343y63e5	16	9	of	of	IN
cord-302756-343y63e5	16	10	increased	increase	VBN
cord-302756-343y63e5	16	11	thrombotic	thrombotic	JJ
cord-302756-343y63e5	16	12	events	event	NNS
cord-302756-343y63e5	16	13	in	in	IN
cord-302756-343y63e5	16	14	these	these	DT
cord-302756-343y63e5	16	15	patients	patient	NNS
cord-302756-343y63e5	16	16	[	[	-LRB-
cord-302756-343y63e5	16	17	3	3	CD
cord-302756-343y63e5	16	18	]	]	-RRB-
cord-302756-343y63e5	16	19	[	[	-LRB-
cord-302756-343y63e5	16	20	4	4	CD
cord-302756-343y63e5	16	21	]	]	-RRB-
cord-302756-343y63e5	16	22	[	[	-LRB-
cord-302756-343y63e5	16	23	5	5	CD
cord-302756-343y63e5	16	24	]	]	-RRB-
cord-302756-343y63e5	16	25	[	[	-LRB-
cord-302756-343y63e5	16	26	6	6	CD
cord-302756-343y63e5	16	27	]	]	-RRB-
cord-302756-343y63e5	16	28	.	.	.
cord-302756-343y63e5	17	1	From	from	IN
cord-302756-343y63e5	17	2	a	a	DT
cord-302756-343y63e5	17	3	laboratory	laboratory	NN
cord-302756-343y63e5	17	4	perspective	perspective	NN
cord-302756-343y63e5	17	5	,	,	,
cord-302756-343y63e5	17	6	this	this	DT
cord-302756-343y63e5	17	7	hypercoagulability	hypercoagulability	NN
cord-302756-343y63e5	17	8	is	be	VBZ
cord-302756-343y63e5	17	9	reflected	reflect	VBN
cord-302756-343y63e5	17	10	in	in	IN
cord-302756-343y63e5	17	11	the	the	DT
cord-302756-343y63e5	17	12	marked	marked	JJ
cord-302756-343y63e5	17	13	elevation	elevation	NN
cord-302756-343y63e5	17	14	of	of	IN
cord-302756-343y63e5	17	15	the	the	DT
cord-302756-343y63e5	17	16	fibrinolytic	fibrinolytic	JJ
cord-302756-343y63e5	17	17	marker	marker	NN
cord-302756-343y63e5	17	18	,	,	,
cord-302756-343y63e5	17	19	D	d	NN
cord-302756-343y63e5	17	20	-	-	HYPH
cord-302756-343y63e5	17	21	dimer	dimer	NN
cord-302756-343y63e5	17	22	,	,	,
cord-302756-343y63e5	17	23	in	in	IN
cord-302756-343y63e5	17	24	almost	almost	RB
cord-302756-343y63e5	17	25	all	all	DT
cord-302756-343y63e5	17	26	hospitalised	hospitalise	VBN
cord-302756-343y63e5	17	27	COVID-19	covid-19	CD
cord-302756-343y63e5	17	28	patients	patient	NNS
cord-302756-343y63e5	17	29	[	[	-LRB-
cord-302756-343y63e5	17	30	7	7	CD
cord-302756-343y63e5	17	31	]	]	-RRB-
cord-302756-343y63e5	17	32	.	.	.
cord-302756-343y63e5	18	1	We	-PRON-	PRP
cord-302756-343y63e5	18	2	must	must	MD
cord-302756-343y63e5	18	3	,	,	,
cord-302756-343y63e5	18	4	therefore	therefore	RB
cord-302756-343y63e5	18	5	,	,	,
cord-302756-343y63e5	18	6	ask	ask	VB
cord-302756-343y63e5	18	7	ourselves	-PRON-	PRP
cord-302756-343y63e5	18	8	what	what	WP
cord-302756-343y63e5	18	9	is	be	VBZ
cord-302756-343y63e5	18	10	the	the	DT
cord-302756-343y63e5	18	11	link	link	NN
cord-302756-343y63e5	18	12	between	between	IN
cord-302756-343y63e5	18	13	the	the	DT
cord-302756-343y63e5	18	14	extremes	extreme	NNS
cord-302756-343y63e5	18	15	of	of	IN
cord-302756-343y63e5	18	16	the	the	DT
cord-302756-343y63e5	18	17	immune	immune	JJ
cord-302756-343y63e5	18	18	system	system	NN
cord-302756-343y63e5	18	19	,	,	,
cord-302756-343y63e5	18	20	presenting	present	VBG
cord-302756-343y63e5	18	21	as	as	IN
cord-302756-343y63e5	18	22	cytokine	cytokine	NN
cord-302756-343y63e5	18	23	storm	storm	NN
cord-302756-343y63e5	18	24	,	,	,
cord-302756-343y63e5	18	25	and	and	CC
cord-302756-343y63e5	18	26	the	the	DT
cord-302756-343y63e5	18	27	extremes	extreme	NNS
cord-302756-343y63e5	18	28	of	of	IN
cord-302756-343y63e5	18	29	coagulation	coagulation	NN
cord-302756-343y63e5	18	30	,	,	,
cord-302756-343y63e5	18	31	presenting	present	VBG
cord-302756-343y63e5	18	32	as	as	IN
cord-302756-343y63e5	18	33	arterial	arterial	JJ
cord-302756-343y63e5	18	34	and	and	CC
cord-302756-343y63e5	18	35	venous	venous	JJ
cord-302756-343y63e5	18	36	thromboembolism	thromboembolism	NN
cord-302756-343y63e5	18	37	?	?	.
cord-302756-343y63e5	19	1	In	in	IN
cord-302756-343y63e5	19	2	embryological	embryological	JJ
cord-302756-343y63e5	19	3	organisms	organism	NNS
cord-302756-343y63e5	19	4	such	such	JJ
cord-302756-343y63e5	19	5	as	as	IN
cord-302756-343y63e5	19	6	the	the	DT
cord-302756-343y63e5	19	7	horse	horse	NN
cord-302756-343y63e5	19	8	-	-	HYPH
cord-302756-343y63e5	19	9	shoe	shoe	NN
cord-302756-343y63e5	19	10	crab	crab	NN
cord-302756-343y63e5	19	11	,	,	,
cord-302756-343y63e5	19	12	the	the	DT
cord-302756-343y63e5	19	13	haemostatic	haemostatic	JJ
cord-302756-343y63e5	19	14	system	system	NN
cord-302756-343y63e5	19	15	and	and	CC
cord-302756-343y63e5	19	16	the	the	DT
cord-302756-343y63e5	19	17	immune	immune	JJ
cord-302756-343y63e5	19	18	system	system	NN
cord-302756-343y63e5	19	19	were	be	VBD
cord-302756-343y63e5	19	20	one	one	CD
cord-302756-343y63e5	19	21	and	and	CC
cord-302756-343y63e5	19	22	the	the	DT
cord-302756-343y63e5	19	23	same	same	JJ
cord-302756-343y63e5	19	24	(	(	-LRB-
cord-302756-343y63e5	19	25	haemolymph	haemolymph	NN
cord-302756-343y63e5	19	26	)	)	-RRB-
cord-302756-343y63e5	20	1	[	[	-LRB-
cord-302756-343y63e5	20	2	8	8	CD
cord-302756-343y63e5	20	3	]	]	-RRB-
cord-302756-343y63e5	20	4	.	.	.
cord-302756-343y63e5	21	1	The	the	DT
cord-302756-343y63e5	21	2	haemostatic	haemostatic	JJ
cord-302756-343y63e5	21	3	system	system	NN
cord-302756-343y63e5	21	4	,	,	,
cord-302756-343y63e5	21	5	by	by	IN
cord-302756-343y63e5	21	6	forming	form	VBG
cord-302756-343y63e5	21	7	a	a	DT
cord-302756-343y63e5	21	8	blood	blood	NN
cord-302756-343y63e5	21	9	clot	clot	NN
cord-302756-343y63e5	21	10	,	,	,
cord-302756-343y63e5	21	11	prevented	prevent	VBD
cord-302756-343y63e5	21	12	the	the	DT
cord-302756-343y63e5	21	13	loss	loss	NN
cord-302756-343y63e5	21	14	of	of	IN
cord-302756-343y63e5	21	15	important	important	JJ
cord-302756-343y63e5	21	16	nutrients	nutrient	NNS
cord-302756-343y63e5	21	17	but	but	CC
cord-302756-343y63e5	21	18	also	also	RB
cord-302756-343y63e5	21	19	formed	form	VBD
cord-302756-343y63e5	21	20	a	a	DT
cord-302756-343y63e5	21	21	barrier	barrier	NN
cord-302756-343y63e5	21	22	to	to	IN
cord-302756-343y63e5	21	23	pathogen	pathogen	NN
cord-302756-343y63e5	21	24	invasion	invasion	NN
cord-302756-343y63e5	21	25	.	.	.
cord-302756-343y63e5	22	1	This	this	DT
cord-302756-343y63e5	22	2	immune	immune	JJ
cord-302756-343y63e5	22	3	function	function	NN
cord-302756-343y63e5	22	4	has	have	VBZ
cord-302756-343y63e5	22	5	been	be	VBN
cord-302756-343y63e5	22	6	explored	explore	VBN
cord-302756-343y63e5	22	7	by	by	IN
cord-302756-343y63e5	22	8	several	several	JJ
cord-302756-343y63e5	22	9	researchers	researcher	NNS
cord-302756-343y63e5	22	10	as	as	IN
cord-302756-343y63e5	22	11	an	an	DT
cord-302756-343y63e5	22	12	immunothrombosis	immunothrombosis	NN
cord-302756-343y63e5	22	13	concept	concept	NN
cord-302756-343y63e5	22	14	[	[	-LRB-
cord-302756-343y63e5	22	15	9	9	CD
cord-302756-343y63e5	22	16	]	]	-RRB-
cord-302756-343y63e5	22	17	.	.	.
cord-302756-343y63e5	23	1	The	the	DT
cord-302756-343y63e5	23	2	various	various	JJ
cord-302756-343y63e5	23	3	components	component	NNS
cord-302756-343y63e5	23	4	of	of	IN
cord-302756-343y63e5	23	5	the	the	DT
cord-302756-343y63e5	23	6	haemostatic	haemostatic	JJ
cord-302756-343y63e5	23	7	system	system	NN
cord-302756-343y63e5	23	8	,	,	,
cord-302756-343y63e5	23	9	including	include	VBG
cord-302756-343y63e5	23	10	the	the	DT
cord-302756-343y63e5	23	11	platelets	platelet	NNS
cord-302756-343y63e5	23	12	,	,	,
cord-302756-343y63e5	23	13	coagulation	coagulation	NN
cord-302756-343y63e5	23	14	factors	factor	NNS
cord-302756-343y63e5	23	15	and	and	CC
cord-302756-343y63e5	23	16	thrombin	thrombin	NN
cord-302756-343y63e5	23	17	,	,	,
cord-302756-343y63e5	23	18	are	be	VBP
cord-302756-343y63e5	23	19	all	all	DT
cord-302756-343y63e5	23	20	immune	immune	JJ
cord-302756-343y63e5	23	21	workers	worker	NNS
cord-302756-343y63e5	23	22	.	.	.
cord-302756-343y63e5	24	1	They	-PRON-	PRP
cord-302756-343y63e5	24	2	function	function	VBP
cord-302756-343y63e5	24	3	as	as	IN
cord-302756-343y63e5	24	4	chemotactic	chemotactic	VBN
cord-302756-343y63e5	24	5	to	to	IN
cord-302756-343y63e5	24	6	the	the	DT
cord-302756-343y63e5	24	7	immune	immune	JJ
cord-302756-343y63e5	24	8	cells	cell	NNS
cord-302756-343y63e5	24	9	,	,	,
cord-302756-343y63e5	24	10	stimulating	stimulate	VBG
cord-302756-343y63e5	24	11	the	the	DT
cord-302756-343y63e5	24	12	various	various	JJ
cord-302756-343y63e5	24	13	immune	immune	JJ
cord-302756-343y63e5	24	14	components	component	NNS
cord-302756-343y63e5	24	15	as	as	RB
cord-302756-343y63e5	24	16	well	well	RB
cord-302756-343y63e5	24	17	as	as	IN
cord-302756-343y63e5	24	18	being	be	VBG
cord-302756-343y63e5	24	19	activated	activate	VBN
cord-302756-343y63e5	24	20	by	by	IN
cord-302756-343y63e5	24	21	the	the	DT
cord-302756-343y63e5	24	22	immune	immune	JJ
cord-302756-343y63e5	24	23	system	system	NN
cord-302756-343y63e5	24	24	themselves	-PRON-	PRP
cord-302756-343y63e5	24	25	[	[	-LRB-
cord-302756-343y63e5	24	26	10	10	CD
cord-302756-343y63e5	24	27	]	]	-RRB-
cord-302756-343y63e5	24	28	[	[	-LRB-
cord-302756-343y63e5	24	29	11	11	CD
cord-302756-343y63e5	24	30	]	]	-RRB-
cord-302756-343y63e5	24	31	[	[	-LRB-
cord-302756-343y63e5	24	32	12	12	CD
cord-302756-343y63e5	24	33	]	]	-RRB-
cord-302756-343y63e5	24	34	.	.	.
cord-302756-343y63e5	25	1	This	this	DT
cord-302756-343y63e5	25	2	bidirectional	bidirectional	JJ
cord-302756-343y63e5	25	3	relationship	relationship	NN
cord-302756-343y63e5	25	4	could	could	MD
cord-302756-343y63e5	25	5	explain	explain	VB
cord-302756-343y63e5	25	6	some	some	DT
cord-302756-343y63e5	25	7	common	common	JJ
cord-302756-343y63e5	25	8	observations	observation	NNS
cord-302756-343y63e5	25	9	with	with	IN
cord-302756-343y63e5	25	10	COVID-19	COVID-19	NNP
cord-302756-343y63e5	25	11	.	.	.
cord-302756-343y63e5	26	1	In	in	IN
cord-302756-343y63e5	26	2	the	the	DT
cord-302756-343y63e5	26	3	pandemic	pandemic	NN
cord-302756-343y63e5	26	4	so	so	RB
cord-302756-343y63e5	26	5	far	far	RB
cord-302756-343y63e5	26	6	,	,	,
cord-302756-343y63e5	26	7	we	-PRON-	PRP
cord-302756-343y63e5	26	8	have	have	VBP
cord-302756-343y63e5	26	9	seen	see	VBN
cord-302756-343y63e5	26	10	that	that	IN
cord-302756-343y63e5	26	11	children	child	NNS
cord-302756-343y63e5	26	12	rarely	rarely	RB
cord-302756-343y63e5	26	13	get	get	VBP
cord-302756-343y63e5	26	14	a	a	DT
cord-302756-343y63e5	26	15	severe	severe	JJ
cord-302756-343y63e5	26	16	illness	illness	NN
cord-302756-343y63e5	26	17	despite	despite	IN
cord-302756-343y63e5	26	18	having	have	VBG
cord-302756-343y63e5	26	19	proven	prove	VBN
cord-302756-343y63e5	26	20	infection	infection	NN
cord-302756-343y63e5	26	21	,	,	,
cord-302756-343y63e5	26	22	although	although	IN
cord-302756-343y63e5	26	23	there	there	EX
cord-302756-343y63e5	26	24	have	have	VBP
cord-302756-343y63e5	26	25	been	be	VBN
cord-302756-343y63e5	26	26	recent	recent	JJ
cord-302756-343y63e5	26	27	reports	report	NNS
cord-302756-343y63e5	26	28	of	of	IN
cord-302756-343y63e5	26	29	a	a	DT
cord-302756-343y63e5	26	30	hyperinflammatory	hyperinflammatory	JJ
cord-302756-343y63e5	26	31	response	response	NN
cord-302756-343y63e5	26	32	in	in	IN
cord-302756-343y63e5	26	33	very	very	RB
cord-302756-343y63e5	26	34	small	small	JJ
cord-302756-343y63e5	26	35	numbers	number	NNS
cord-302756-343y63e5	26	36	of	of	IN
cord-302756-343y63e5	26	37	children	child	NNS
cord-302756-343y63e5	26	38	[	[	-LRB-
cord-302756-343y63e5	26	39	13	13	CD
cord-302756-343y63e5	26	40	]	]	-RRB-
cord-302756-343y63e5	26	41	.	.	.
cord-302756-343y63e5	27	1	This	this	DT
cord-302756-343y63e5	27	2	rarity	rarity	NN
cord-302756-343y63e5	27	3	of	of	IN
cord-302756-343y63e5	27	4	severe	severe	JJ
cord-302756-343y63e5	27	5	disease	disease	NN
cord-302756-343y63e5	27	6	may	may	MD
cord-302756-343y63e5	27	7	be	be	VB
cord-302756-343y63e5	27	8	explained	explain	VBN
cord-302756-343y63e5	27	9	by	by	IN
cord-302756-343y63e5	27	10	the	the	DT
cord-302756-343y63e5	27	11	rarity	rarity	NN
cord-302756-343y63e5	27	12	of	of	IN
cord-302756-343y63e5	27	13	thrombotic	thrombotic	JJ
cord-302756-343y63e5	27	14	complications	complication	NNS
cord-302756-343y63e5	27	15	in	in	IN
cord-302756-343y63e5	27	16	the	the	DT
cord-302756-343y63e5	27	17	paediatric	paediatric	JJ
cord-302756-343y63e5	27	18	age	age	NN
cord-302756-343y63e5	27	19	group	group	NN
cord-302756-343y63e5	27	20	in	in	IN
cord-302756-343y63e5	27	21	the	the	DT
cord-302756-343y63e5	27	22	absence	absence	NN
cord-302756-343y63e5	27	23	of	of	IN
cord-302756-343y63e5	27	24	an	an	DT
cord-302756-343y63e5	27	25	underlying	underlie	VBG
cord-302756-343y63e5	27	26	cancer	cancer	NN
cord-302756-343y63e5	27	27	or	or	CC
cord-302756-343y63e5	27	28	a	a	DT
cord-302756-343y63e5	27	29	central	central	JJ
cord-302756-343y63e5	27	30	venous	venous	JJ
cord-302756-343y63e5	27	31	access	access	NN
cord-302756-343y63e5	27	32	device	device	NN
cord-302756-343y63e5	27	33	[	[	-LRB-
cord-302756-343y63e5	27	34	14	14	CD
cord-302756-343y63e5	27	35	]	]	-RRB-
cord-302756-343y63e5	27	36	.	.	.
cord-302756-343y63e5	28	1	Similarly	similarly	RB
cord-302756-343y63e5	28	2	pregnant	pregnant	JJ
cord-302756-343y63e5	28	3	women	woman	NNS
cord-302756-343y63e5	28	4	,	,	,
cord-302756-343y63e5	28	5	despite	despite	IN
cord-302756-343y63e5	28	6	being	be	VBG
cord-302756-343y63e5	28	7	at	at	IN
cord-302756-343y63e5	28	8	risk	risk	NN
cord-302756-343y63e5	28	9	of	of	IN
cord-302756-343y63e5	28	10	clotting	clotting	NN
cord-302756-343y63e5	28	11	problems	problem	NNS
cord-302756-343y63e5	28	12	,	,	,
cord-302756-343y63e5	28	13	tend	tend	VBP
cord-302756-343y63e5	28	14	to	to	TO
cord-302756-343y63e5	28	15	have	have	VB
cord-302756-343y63e5	28	16	milder	mild	JJR
cord-302756-343y63e5	28	17	illness	illness	NN
cord-302756-343y63e5	28	18	.	.	.
cord-302756-343y63e5	29	1	This	this	DT
cord-302756-343y63e5	29	2	may	may	MD
cord-302756-343y63e5	29	3	be	be	VB
cord-302756-343y63e5	29	4	because	because	IN
cord-302756-343y63e5	29	5	their	-PRON-	PRP$
cord-302756-343y63e5	29	6	immune	immune	JJ
cord-302756-343y63e5	29	7	system	system	NN
cord-302756-343y63e5	29	8	is	be	VBZ
cord-302756-343y63e5	29	9	suppressed	suppress	VBN
cord-302756-343y63e5	29	10	during	during	IN
cord-302756-343y63e5	29	11	the	the	DT
cord-302756-343y63e5	29	12	gestational	gestational	JJ
cord-302756-343y63e5	29	13	period	period	NN
cord-302756-343y63e5	29	14	to	to	TO
cord-302756-343y63e5	29	15	avoid	avoid	VB
cord-302756-343y63e5	29	16	foetal	foetal	JJ
cord-302756-343y63e5	29	17	rejection	rejection	NN
cord-302756-343y63e5	29	18	and	and	CC
cord-302756-343y63e5	30	1	hence	hence	RB
cord-302756-343y63e5	30	2	the	the	DT
cord-302756-343y63e5	30	3	double	double	JJ
cord-302756-343y63e5	30	4	hit	hit	NN
cord-302756-343y63e5	30	5	of	of	IN
cord-302756-343y63e5	30	6	immunothrombosis	immunothrombosis	NN
cord-302756-343y63e5	30	7	does	do	VBZ
cord-302756-343y63e5	30	8	not	not	RB
cord-302756-343y63e5	30	9	come	come	VB
cord-302756-343y63e5	30	10	into	into	IN
cord-302756-343y63e5	30	11	play	play	NN
cord-302756-343y63e5	30	12	[	[	-LRB-
cord-302756-343y63e5	30	13	15	15	CD
cord-302756-343y63e5	30	14	]	]	-RRB-
cord-302756-343y63e5	30	15	.	.	.
cord-302756-343y63e5	31	1	On	on	IN
cord-302756-343y63e5	31	2	the	the	DT
cord-302756-343y63e5	31	3	other	other	JJ
cord-302756-343y63e5	31	4	hand	hand	NN
cord-302756-343y63e5	31	5	,	,	,
cord-302756-343y63e5	31	6	older	old	JJR
cord-302756-343y63e5	31	7	individuals	individual	NNS
cord-302756-343y63e5	31	8	,	,	,
cord-302756-343y63e5	31	9	who	who	WP
cord-302756-343y63e5	31	10	are	be	VBP
cord-302756-343y63e5	31	11	more	more	RBR
cord-302756-343y63e5	31	12	prone	prone	JJ
cord-302756-343y63e5	31	13	to	to	IN
cord-302756-343y63e5	31	14	getting	get	VBG
cord-302756-343y63e5	31	15	thrombotic	thrombotic	JJ
cord-302756-343y63e5	31	16	complications	complication	NNS
cord-302756-343y63e5	31	17	in	in	IN
cord-302756-343y63e5	31	18	the	the	DT
cord-302756-343y63e5	31	19	pre	pre	JJ
cord-302756-343y63e5	31	20	-	-	JJ
cord-302756-343y63e5	31	21	COVID-19	covid-19	JJ
cord-302756-343y63e5	31	22	era	era	NN
cord-302756-343y63e5	31	23	,	,	,
cord-302756-343y63e5	31	24	are	be	VBP
cord-302756-343y63e5	31	25	more	more	RBR
cord-302756-343y63e5	31	26	likely	likely	JJ
cord-302756-343y63e5	31	27	to	to	TO
cord-302756-343y63e5	31	28	get	get	VB
cord-302756-343y63e5	31	29	severe	severe	JJ
cord-302756-343y63e5	31	30	disease	disease	NN
cord-302756-343y63e5	31	31	.	.	.
cord-302756-343y63e5	32	1	The	the	DT
cord-302756-343y63e5	32	2	differences	difference	NNS
cord-302756-343y63e5	32	3	in	in	IN
cord-302756-343y63e5	32	4	mortality	mortality	NN
cord-302756-343y63e5	32	5	between	between	IN
cord-302756-343y63e5	32	6	the	the	DT
cord-302756-343y63e5	32	7	South	South	NNP
cord-302756-343y63e5	32	8	East	East	NNP
cord-302756-343y63e5	32	9	Asian	asian	JJ
cord-302756-343y63e5	32	10	and	and	CC
cord-302756-343y63e5	32	11	Western	western	JJ
cord-302756-343y63e5	32	12	cohorts	cohort	NNS
cord-302756-343y63e5	32	13	affected	affect	VBN
cord-302756-343y63e5	32	14	by	by	IN
cord-302756-343y63e5	32	15	COVID-19	COVID-19	NNP
cord-302756-343y63e5	32	16	could	could	MD
cord-302756-343y63e5	32	17	also	also	RB
cord-302756-343y63e5	32	18	be	be	VB
cord-302756-343y63e5	32	19	explained	explain	VBN
cord-302756-343y63e5	32	20	by	by	IN
cord-302756-343y63e5	32	21	the	the	DT
cord-302756-343y63e5	32	22	lack	lack	NN
cord-302756-343y63e5	32	23	of	of	IN
cord-302756-343y63e5	32	24	prothrombotic	prothrombotic	JJ
cord-302756-343y63e5	32	25	tendencies	tendency	NNS
cord-302756-343y63e5	32	26	in	in	IN
cord-302756-343y63e5	32	27	the	the	DT
cord-302756-343y63e5	32	28	South	South	NNP
cord-302756-343y63e5	32	29	East	east	JJ
cord-302756-343y63e5	32	30	Asian	asian	JJ
cord-302756-343y63e5	32	31	population	population	NN
cord-302756-343y63e5	32	32	[	[	-LRB-
cord-302756-343y63e5	32	33	16	16	CD
cord-302756-343y63e5	32	34	]	]	-RRB-
cord-302756-343y63e5	32	35	.	.	.
cord-302756-343y63e5	33	1	We	-PRON-	PRP
cord-302756-343y63e5	33	2	must	must	MD
cord-302756-343y63e5	33	3	wonder	wonder	VB
cord-302756-343y63e5	33	4	,	,	,
cord-302756-343y63e5	33	5	however	however	RB
cord-302756-343y63e5	33	6	,	,	,
cord-302756-343y63e5	33	7	why	why	WRB
cord-302756-343y63e5	33	8	some	some	DT
cord-302756-343y63e5	33	9	Western	western	JJ
cord-302756-343y63e5	33	10	patients	patient	NNS
cord-302756-343y63e5	33	11	affected	affect	VBN
cord-302756-343y63e5	33	12	by	by	IN
cord-302756-343y63e5	33	13	the	the	DT
cord-302756-343y63e5	33	14	virus	virus	NN
cord-302756-343y63e5	33	15	get	get	VBP
cord-302756-343y63e5	33	16	severe	severe	JJ
cord-302756-343y63e5	33	17	respiratory	respiratory	JJ
cord-302756-343y63e5	33	18	compromise	compromise	NN
cord-302756-343y63e5	33	19	requiring	require	VBG
cord-302756-343y63e5	33	20	critical	critical	JJ
cord-302756-343y63e5	33	21	care	care	NN
cord-302756-343y63e5	33	22	support	support	NN
cord-302756-343y63e5	33	23	whilst	whilst	IN
cord-302756-343y63e5	33	24	others	other	NNS
cord-302756-343y63e5	33	25	have	have	VBP
cord-302756-343y63e5	33	26	a	a	DT
cord-302756-343y63e5	33	27	relatively	relatively	RB
cord-302756-343y63e5	33	28	mild	mild	JJ
cord-302756-343y63e5	33	29	illness	illness	NN
cord-302756-343y63e5	33	30	?	?	.
cord-302756-343y63e5	34	1	This	this	DT
cord-302756-343y63e5	34	2	article	article	NN
cord-302756-343y63e5	34	3	is	be	VBZ
cord-302756-343y63e5	34	4	protected	protect	VBN
cord-302756-343y63e5	34	5	by	by	IN
cord-302756-343y63e5	34	6	copyright	copyright	NN
cord-302756-343y63e5	34	7	.	.	.
cord-302756-343y63e5	35	1	All	all	DT
cord-302756-343y63e5	35	2	rights	right	NNS
cord-302756-343y63e5	35	3	reserved	reserve	VBN
cord-302756-343y63e5	35	4	SARS	SARS	NNP
cord-302756-343y63e5	35	5	-	-	HYPH
cord-302756-343y63e5	35	6	Cov-2	Cov-2	NNP
cord-302756-343y63e5	35	7	gains	gain	NNS
cord-302756-343y63e5	35	8	entry	entry	NN
cord-302756-343y63e5	35	9	predominantly	predominantly	RB
cord-302756-343y63e5	35	10	through	through	IN
cord-302756-343y63e5	35	11	the	the	DT
cord-302756-343y63e5	35	12	lungs	lung	NNS
cord-302756-343y63e5	35	13	.	.	.
cord-302756-343y63e5	36	1	In	in	IN
cord-302756-343y63e5	36	2	the	the	DT
cord-302756-343y63e5	36	3	lungs	lung	NNS
cord-302756-343y63e5	36	4	,	,	,
cord-302756-343y63e5	36	5	a	a	DT
cord-302756-343y63e5	36	6	localised	localised	JJ
cord-302756-343y63e5	36	7	coagulation	coagulation	NN
cord-302756-343y63e5	36	8	system	system	NN
cord-302756-343y63e5	36	9	or	or	CC
cord-302756-343y63e5	36	10	broncho	broncho	JJ
cord-302756-343y63e5	36	11	-	-	HYPH
cord-302756-343y63e5	36	12	alveolar	alveolar	NN
cord-302756-343y63e5	36	13	haemostasis	haemostasis	NN
cord-302756-343y63e5	36	14	is	be	VBZ
cord-302756-343y63e5	36	15	present	present	JJ
cord-302756-343y63e5	36	16	which	which	WDT
cord-302756-343y63e5	36	17	tries	try	VBZ
cord-302756-343y63e5	36	18	to	to	TO
cord-302756-343y63e5	36	19	fight	fight	VB
cord-302756-343y63e5	36	20	the	the	DT
cord-302756-343y63e5	36	21	infection	infection	NN
cord-302756-343y63e5	36	22	along	along	IN
cord-302756-343y63e5	36	23	with	with	IN
cord-302756-343y63e5	36	24	the	the	DT
cord-302756-343y63e5	36	25	immune	immune	JJ
cord-302756-343y63e5	36	26	cells	cell	NNS
cord-302756-343y63e5	36	27	[	[	-LRB-
cord-302756-343y63e5	36	28	17	17	CD
cord-302756-343y63e5	36	29	]	]	-RRB-
cord-302756-343y63e5	36	30	.	.	.
cord-302756-343y63e5	37	1	The	the	DT
cord-302756-343y63e5	37	2	proof	proof	NN
cord-302756-343y63e5	37	3	for	for	IN
cord-302756-343y63e5	37	4	this	this	DT
cord-302756-343y63e5	37	5	lung	lung	NN
cord-302756-343y63e5	37	6	-	-	HYPH
cord-302756-343y63e5	37	7	specific	specific	JJ
cord-302756-343y63e5	37	8	clot	clot	NN
cord-302756-343y63e5	37	9	formation	formation	NN
cord-302756-343y63e5	37	10	comes	come	VBZ
cord-302756-343y63e5	37	11	from	from	IN
cord-302756-343y63e5	37	12	two	two	CD
cord-302756-343y63e5	37	13	things	thing	NNS
cord-302756-343y63e5	37	14	.	.	.
cord-302756-343y63e5	38	1	Firstly	firstly	RB
cord-302756-343y63e5	38	2	,	,	,
cord-302756-343y63e5	38	3	the	the	DT
cord-302756-343y63e5	38	4	marked	marked	JJ
cord-302756-343y63e5	38	5	acute	acute	JJ
cord-302756-343y63e5	38	6	phase	phase	NN
cord-302756-343y63e5	38	7	response	response	NN
cord-302756-343y63e5	38	8	includes	include	VBZ
cord-302756-343y63e5	38	9	platelets	platelet	NNS
cord-302756-343y63e5	38	10	and	and	CC
cord-302756-343y63e5	38	11	fibrinogen	fibrinogen	NN
cord-302756-343y63e5	38	12	in	in	IN
cord-302756-343y63e5	38	13	addition	addition	NN
cord-302756-343y63e5	38	14	to	to	IN
cord-302756-343y63e5	38	15	other	other	JJ
cord-302756-343y63e5	38	16	well	well	RB
cord-302756-343y63e5	38	17	-	-	HYPH
cord-302756-343y63e5	38	18	known	know	VBN
cord-302756-343y63e5	38	19	markers	marker	NNS
cord-302756-343y63e5	38	20	such	such	JJ
cord-302756-343y63e5	38	21	as	as	IN
cord-302756-343y63e5	38	22	C	C	NNP
cord-302756-343y63e5	38	23	-	-	HYPH
cord-302756-343y63e5	38	24	reactive	reactive	JJ
cord-302756-343y63e5	38	25	protein	protein	NN
cord-302756-343y63e5	38	26	and	and	CC
cord-302756-343y63e5	38	27	ferritin	ferritin	NN
cord-302756-343y63e5	38	28	.	.	.
cord-302756-343y63e5	39	1	Platelet	platelet	NN
cord-302756-343y63e5	39	2	counts	count	NNS
cord-302756-343y63e5	39	3	are	be	VBP
cord-302756-343y63e5	39	4	increased	increase	VBN
cord-302756-343y63e5	39	5	in	in	IN
cord-302756-343y63e5	39	6	these	these	DT
cord-302756-343y63e5	39	7	patients	patient	NNS
cord-302756-343y63e5	39	8	in	in	IN
cord-302756-343y63e5	39	9	the	the	DT
cord-302756-343y63e5	39	10	initial	initial	JJ
cord-302756-343y63e5	39	11	stages	stage	NNS
cord-302756-343y63e5	39	12	(	(	-LRB-
cord-302756-343y63e5	39	13	uncommonly	uncommonly	RB
cord-302756-343y63e5	39	14	reported	report	VBN
cord-302756-343y63e5	39	15	in	in	IN
cord-302756-343y63e5	39	16	patients	patient	NNS
cord-302756-343y63e5	39	17	with	with	IN
cord-302756-343y63e5	39	18	infectious	infectious	JJ
cord-302756-343y63e5	39	19	diseases	disease	NNS
cord-302756-343y63e5	39	20	)	)	-RRB-
cord-302756-343y63e5	39	21	and	and	CC
cord-302756-343y63e5	39	22	are	be	VBP
cord-302756-343y63e5	39	23	almost	almost	RB
cord-302756-343y63e5	39	24	never	never	RB
cord-302756-343y63e5	39	25	severely	severely	RB
cord-302756-343y63e5	39	26	low	low	JJ
cord-302756-343y63e5	39	27	,	,	,
cord-302756-343y63e5	39	28	even	even	RB
cord-302756-343y63e5	39	29	in	in	IN
cord-302756-343y63e5	39	30	critically	critically	RB
cord-302756-343y63e5	39	31	ill	ill	JJ
cord-302756-343y63e5	39	32	COVID-19	covid-19	CD
cord-302756-343y63e5	39	33	patients	patient	NNS
cord-302756-343y63e5	39	34	[	[	-LRB-
cord-302756-343y63e5	39	35	18	18	CD
cord-302756-343y63e5	39	36	]	]	-RRB-
cord-302756-343y63e5	39	37	.	.	.
cord-302756-343y63e5	40	1	Similarly	similarly	RB
cord-302756-343y63e5	40	2	,	,	,
cord-302756-343y63e5	40	3	fibrinogen	fibrinogen	NN
cord-302756-343y63e5	40	4	is	be	VBZ
cord-302756-343y63e5	40	5	markedly	markedly	RB
cord-302756-343y63e5	40	6	raised	raise	VBN
cord-302756-343y63e5	40	7	in	in	IN
cord-302756-343y63e5	40	8	these	these	DT
cord-302756-343y63e5	40	9	patients	patient	NNS
cord-302756-343y63e5	40	10	and	and	CC
cord-302756-343y63e5	40	11	has	have	VBZ
cord-302756-343y63e5	40	12	been	be	VBN
cord-302756-343y63e5	40	13	historically	historically	RB
cord-302756-343y63e5	40	14	recognised	recognise	VBN
cord-302756-343y63e5	40	15	as	as	IN
cord-302756-343y63e5	40	16	a	a	DT
cord-302756-343y63e5	40	17	marker	marker	NN
cord-302756-343y63e5	40	18	of	of	IN
cord-302756-343y63e5	40	19	hypercoagulability	hypercoagulability	NN
cord-302756-343y63e5	40	20	[	[	-LRB-
cord-302756-343y63e5	40	21	19	19	CD
cord-302756-343y63e5	40	22	]	]	-RRB-
cord-302756-343y63e5	40	23	.	.	.
cord-302756-343y63e5	41	1	Secondly	secondly	RB
cord-302756-343y63e5	41	2	,	,	,
cord-302756-343y63e5	41	3	post	post	JJ
cord-302756-343y63e5	41	4	-	-	JJ
cord-302756-343y63e5	41	5	mortem	mortem	JJ
cord-302756-343y63e5	41	6	examinations	examination	NNS
cord-302756-343y63e5	41	7	have	have	VBP
cord-302756-343y63e5	41	8	found	find	VBN
cord-302756-343y63e5	41	9	evidence	evidence	NN
cord-302756-343y63e5	41	10	of	of	IN
cord-302756-343y63e5	41	11	pulmonary	pulmonary	JJ
cord-302756-343y63e5	41	12	microthrombi	microthrombi	NN
cord-302756-343y63e5	41	13	in	in	IN
cord-302756-343y63e5	41	14	patients	patient	NNS
cord-302756-343y63e5	41	15	with	with	IN
cord-302756-343y63e5	41	16	COVID-19	COVID-19	NNP
cord-302756-343y63e5	41	17	[	[	-LRB-
cord-302756-343y63e5	41	18	20	20	CD
cord-302756-343y63e5	41	19	]	]	-RRB-
cord-302756-343y63e5	41	20	.	.	.
cord-302756-343y63e5	42	1	There	there	EX
cord-302756-343y63e5	42	2	are	be	VBP
cord-302756-343y63e5	42	3	also	also	RB
cord-302756-343y63e5	42	4	suggestions	suggestion	NNS
cord-302756-343y63e5	42	5	that	that	IN
cord-302756-343y63e5	42	6	the	the	DT
cord-302756-343y63e5	42	7	different	different	JJ
cord-302756-343y63e5	42	8	ventilatory	ventilatory	JJ
cord-302756-343y63e5	42	9	patterns	pattern	NNS
cord-302756-343y63e5	42	10	in	in	IN
cord-302756-343y63e5	42	11	COVID-19	COVID-19	NNP
cord-302756-343y63e5	42	12	may	may	MD
cord-302756-343y63e5	42	13	suggest	suggest	VB
cord-302756-343y63e5	42	14	microthrombi	microthrombi	NNP
cord-302756-343y63e5	42	15	to	to	TO
cord-302756-343y63e5	42	16	be	be	VB
cord-302756-343y63e5	42	17	a	a	DT
cord-302756-343y63e5	42	18	key	key	JJ
cord-302756-343y63e5	42	19	component	component	NN
cord-302756-343y63e5	42	20	of	of	IN
cord-302756-343y63e5	42	21	clinical	clinical	JJ
cord-302756-343y63e5	42	22	deterioration	deterioration	NN
cord-302756-343y63e5	42	23	[	[	-LRB-
cord-302756-343y63e5	42	24	21	21	CD
cord-302756-343y63e5	42	25	]	]	-RRB-
cord-302756-343y63e5	42	26	.	.	.
cord-302756-343y63e5	43	1	In	in	IN
cord-302756-343y63e5	43	2	non	non	JJ
cord-302756-343y63e5	43	3	-	-	JJ
cord-302756-343y63e5	43	4	severe	severe	JJ
cord-302756-343y63e5	43	5	COVID-19	covid-19	NN
cord-302756-343y63e5	43	6	,	,	,
cord-302756-343y63e5	43	7	these	these	DT
cord-302756-343y63e5	43	8	microthrombi	microthrombi	NN
cord-302756-343y63e5	43	9	are	be	VBP
cord-302756-343y63e5	43	10	broken	break	VBN
cord-302756-343y63e5	43	11	down	down	RP
cord-302756-343y63e5	43	12	by	by	IN
cord-302756-343y63e5	43	13	the	the	DT
cord-302756-343y63e5	43	14	highly	highly	RB
cord-302756-343y63e5	43	15	active	active	JJ
cord-302756-343y63e5	43	16	fibrinolytic	fibrinolytic	JJ
cord-302756-343y63e5	43	17	function	function	NN
cord-302756-343y63e5	43	18	in	in	IN
cord-302756-343y63e5	43	19	the	the	DT
cord-302756-343y63e5	43	20	lungs	lung	NNS
cord-302756-343y63e5	43	21	to	to	TO
cord-302756-343y63e5	43	22	allow	allow	VB
cord-302756-343y63e5	43	23	gas	gas	NN
cord-302756-343y63e5	43	24	exchange	exchange	NN
cord-302756-343y63e5	43	25	which	which	WDT
cord-302756-343y63e5	43	26	is	be	VBZ
cord-302756-343y63e5	43	27	noted	note	VBN
cord-302756-343y63e5	43	28	as	as	IN
cord-302756-343y63e5	43	29	an	an	DT
cord-302756-343y63e5	43	30	elevation	elevation	NN
cord-302756-343y63e5	43	31	in	in	IN
cord-302756-343y63e5	43	32	D	d	NN
cord-302756-343y63e5	43	33	-	-	HYPH
cord-302756-343y63e5	43	34	dimers	dimer	NNS
cord-302756-343y63e5	43	35	.	.	.
cord-302756-343y63e5	44	1	In	in	IN
cord-302756-343y63e5	44	2	severely	severely	RB
cord-302756-343y63e5	44	3	ill	ill	JJ
cord-302756-343y63e5	44	4	patients	patient	NNS
cord-302756-343y63e5	44	5	,	,	,
cord-302756-343y63e5	44	6	the	the	DT
cord-302756-343y63e5	44	7	pulmonary	pulmonary	JJ
cord-302756-343y63e5	44	8	coagulation	coagulation	NN
cord-302756-343y63e5	44	9	system	system	NN
cord-302756-343y63e5	44	10	becomes	become	VBZ
cord-302756-343y63e5	44	11	markedly	markedly	RB
cord-302756-343y63e5	44	12	activated	activate	VBN
cord-302756-343y63e5	44	13	.	.	.
cord-302756-343y63e5	45	1	This	this	DT
cord-302756-343y63e5	45	2	would	would	MD
cord-302756-343y63e5	45	3	be	be	VB
cord-302756-343y63e5	45	4	clinically	clinically	RB
cord-302756-343y63e5	45	5	manifest	manifest	JJ
cord-302756-343y63e5	45	6	as	as	IN
cord-302756-343y63e5	45	7	increased	increase	VBN
cord-302756-343y63e5	45	8	oxygen	oxygen	NN
cord-302756-343y63e5	45	9	requirements	requirement	NNS
cord-302756-343y63e5	45	10	and	and	CC
cord-302756-343y63e5	45	11	possibly	possibly	RB
cord-302756-343y63e5	45	12	as	as	IN
cord-302756-343y63e5	45	13	an	an	DT
cord-302756-343y63e5	45	14	increased	increase	VBN
cord-302756-343y63e5	45	15	incidence	incidence	NN
cord-302756-343y63e5	45	16	of	of	IN
cord-302756-343y63e5	45	17	renal	renal	JJ
cord-302756-343y63e5	45	18	impairment	impairment	NN
cord-302756-343y63e5	45	19	(	(	-LRB-
cord-302756-343y63e5	45	20	latest	late	JJS
cord-302756-343y63e5	45	21	ICNARC	ICNARC	NNP
cord-302756-343y63e5	45	22	data	datum	NNS
cord-302756-343y63e5	45	23	 	 	_SP
cord-302756-343y63e5	45	24	Based	Based	NNP
cord-302756-343y63e5	45	25	on	on	IN
cord-302756-343y63e5	45	26	several	several	JJ
cord-302756-343y63e5	45	27	reports	report	NNS
cord-302756-343y63e5	45	28	of	of	IN
cord-302756-343y63e5	45	29	hypercoagulability	hypercoagulability	NN
cord-302756-343y63e5	45	30	,	,	,
cord-302756-343y63e5	45	31	it	-PRON-	PRP
cord-302756-343y63e5	45	32	is	be	VBZ
cord-302756-343y63e5	45	33	now	now	RB
cord-302756-343y63e5	45	34	recognised	recognise	VBN
cord-302756-343y63e5	45	35	that	that	IN
cord-302756-343y63e5	45	36	all	all	DT
cord-302756-343y63e5	45	37	patients	patient	NNS
cord-302756-343y63e5	45	38	with	with	IN
cord-302756-343y63e5	45	39	COVID-19	covid-19	JJ
cord-302756-343y63e5	45	40	requiring	require	VBG
cord-302756-343y63e5	45	41	hospitalisation	hospitalisation	NN
cord-302756-343y63e5	45	42	require	require	VBP
cord-302756-343y63e5	45	43	prophylactic	prophylactic	JJ
cord-302756-343y63e5	45	44	anticoagulation	anticoagulation	NN
cord-302756-343y63e5	45	45	in	in	IN
cord-302756-343y63e5	45	46	the	the	DT
cord-302756-343y63e5	45	47	absence	absence	NN
cord-302756-343y63e5	45	48	of	of	IN
cord-302756-343y63e5	45	49	absolute	absolute	JJ
cord-302756-343y63e5	45	50	contraindications	contraindication	NNS
cord-302756-343y63e5	45	51	[	[	-LRB-
cord-302756-343y63e5	45	52	22	22	CD
cord-302756-343y63e5	45	53	,	,	,
cord-302756-343y63e5	45	54	23	23	CD
cord-302756-343y63e5	45	55	]	]	-RRB-
cord-302756-343y63e5	45	56	.	.	.
cord-302756-343y63e5	46	1	However	however	RB
cord-302756-343y63e5	46	2	,	,	,
cord-302756-343y63e5	46	3	in	in	IN
cord-302756-343y63e5	46	4	patients	patient	NNS
cord-302756-343y63e5	46	5	where	where	WRB
cord-302756-343y63e5	46	6	localised	localised	JJ
cord-302756-343y63e5	46	7	pulmonary	pulmonary	JJ
cord-302756-343y63e5	46	8	coagulopathy	coagulopathy	NN
cord-302756-343y63e5	46	9	may	may	MD
cord-302756-343y63e5	46	10	progress	progress	VB
cord-302756-343y63e5	46	11	or	or	CC
cord-302756-343y63e5	46	12	have	have	VBP
cord-302756-343y63e5	46	13	already	already	RB
cord-302756-343y63e5	46	14	become	become	VBN
cord-302756-343y63e5	46	15	systemic	systemic	JJ
cord-302756-343y63e5	46	16	,	,	,
cord-302756-343y63e5	46	17	prophylactic	prophylactic	JJ
cord-302756-343y63e5	46	18	anticoagulation	anticoagulation	NN
cord-302756-343y63e5	46	19	might	may	MD
cord-302756-343y63e5	46	20	be	be	VB
cord-302756-343y63e5	46	21	inadequate	inadequate	JJ
cord-302756-343y63e5	46	22	.	.	.
cord-302756-343y63e5	47	1	There	there	EX
cord-302756-343y63e5	47	2	are	be	VBP
cord-302756-343y63e5	47	3	currently	currently	RB
cord-302756-343y63e5	47	4	several	several	JJ
cord-302756-343y63e5	47	5	trials	trial	NNS
cord-302756-343y63e5	47	6	looking	look	VBG
cord-302756-343y63e5	47	7	at	at	IN
cord-302756-343y63e5	47	8	an	an	DT
cord-302756-343y63e5	47	9	increased	increase	VBN
cord-302756-343y63e5	47	10	dose	dose	NN
cord-302756-343y63e5	47	11	of	of	IN
cord-302756-343y63e5	47	12	anticoagulation	anticoagulation	NN
cord-302756-343y63e5	47	13	,	,	,
cord-302756-343y63e5	47	14	even	even	RB
cord-302756-343y63e5	47	15	therapeutic	therapeutic	JJ
cord-302756-343y63e5	47	16	anticoagulation	anticoagulation	NN
cord-302756-343y63e5	47	17	in	in	IN
cord-302756-343y63e5	47	18	such	such	JJ
cord-302756-343y63e5	47	19	patients	patient	NNS
cord-302756-343y63e5	47	20	.	.	.
cord-302756-343y63e5	48	1	It	-PRON-	PRP
cord-302756-343y63e5	48	2	is	be	VBZ
cord-302756-343y63e5	48	3	important	important	JJ
cord-302756-343y63e5	48	4	to	to	TO
cord-302756-343y63e5	48	5	bear	bear	VB
cord-302756-343y63e5	48	6	in	in	IN
cord-302756-343y63e5	48	7	mind	mind	NN
cord-302756-343y63e5	48	8	that	that	IN
cord-302756-343y63e5	48	9	systemic	systemic	JJ
cord-302756-343y63e5	48	10	coagulopathy	coagulopathy	NN
cord-302756-343y63e5	48	11	may	may	MD
cord-302756-343y63e5	48	12	not	not	RB
cord-302756-343y63e5	48	13	be	be	VB
cord-302756-343y63e5	48	14	treated	treat	VBN
cord-302756-343y63e5	48	15	with	with	IN
cord-302756-343y63e5	48	16	full	full	JJ
cord-302756-343y63e5	48	17	-	-	HYPH
cord-302756-343y63e5	48	18	dose	dose	NN
cord-302756-343y63e5	48	19	anticoagulation	anticoagulation	NN
cord-302756-343y63e5	48	20	in	in	IN
cord-302756-343y63e5	48	21	all	all	DT
cord-302756-343y63e5	48	22	cases	case	NNS
cord-302756-343y63e5	48	23	.	.	.
cord-302756-343y63e5	49	1	It	-PRON-	PRP
cord-302756-343y63e5	49	2	is	be	VBZ
cord-302756-343y63e5	49	3	likely	likely	JJ
cord-302756-343y63e5	49	4	that	that	IN
cord-302756-343y63e5	49	5	extra	extra	JJ
cord-302756-343y63e5	49	6	-	-	JJ
cord-302756-343y63e5	49	7	pulmonary	pulmonary	JJ
cord-302756-343y63e5	49	8	coagulopathy	coagulopathy	NN
cord-302756-343y63e5	49	9	requires	require	VBZ
cord-302756-343y63e5	49	10	more	more	RBR
cord-302756-343y63e5	49	11	aggressive	aggressive	JJ
cord-302756-343y63e5	49	12	anti	anti	JJ
cord-302756-343y63e5	49	13	-	-	JJ
cord-302756-343y63e5	49	14	thrombotic	thrombotic	JJ
cord-302756-343y63e5	49	15	therapies	therapy	NNS
cord-302756-343y63e5	49	16	(	(	-LRB-
cord-302756-343y63e5	49	17	for	for	IN
cord-302756-343y63e5	49	18	example	example	NN
cord-302756-343y63e5	49	19	additional	additional	JJ
cord-302756-343y63e5	49	20	antiplatelet	antiplatelet	NN
cord-302756-343y63e5	49	21	drugs	drug	NNS
cord-302756-343y63e5	49	22	or	or	CC
cord-302756-343y63e5	49	23	thrombolysis	thrombolysis	NN
cord-302756-343y63e5	49	24	)	)	-RRB-
cord-302756-343y63e5	49	25	and	and	CC
cord-302756-343y63e5	49	26	treatments	treatment	NNS
cord-302756-343y63e5	49	27	which	which	WDT
cord-302756-343y63e5	49	28	can	can	MD
cord-302756-343y63e5	49	29	impact	impact	VB
cord-302756-343y63e5	49	30	on	on	IN
cord-302756-343y63e5	49	31	the	the	DT
cord-302756-343y63e5	49	32	immunothrombosis	immunothrombosis	NN
cord-302756-343y63e5	49	33	models	model	NNS
cord-302756-343y63e5	49	34	(	(	-LRB-
cord-302756-343y63e5	49	35	for	for	IN
cord-302756-343y63e5	49	36	example	example	NN
cord-302756-343y63e5	49	37	immunomodulatory	immunomodulatory	JJ
cord-302756-343y63e5	49	38	agents	agent	NNS
cord-302756-343y63e5	49	39	and	and	CC
cord-302756-343y63e5	49	40	anti	anti	JJ
cord-302756-343y63e5	49	41	-	-	JJ
cord-302756-343y63e5	49	42	complement	complement	JJ
cord-302756-343y63e5	49	43	drugs	drug	NNS
cord-302756-343y63e5	49	44	)	)	-RRB-
cord-302756-343y63e5	49	45	[	[	-LRB-
cord-302756-343y63e5	49	46	24	24	CD
cord-302756-343y63e5	49	47	]	]	-RRB-
cord-302756-343y63e5	49	48	[	[	-LRB-
cord-302756-343y63e5	49	49	25	25	CD
cord-302756-343y63e5	49	50	]	]	-RRB-
cord-302756-343y63e5	49	51	[	[	-LRB-
cord-302756-343y63e5	49	52	26	26	CD
cord-302756-343y63e5	49	53	]	]	-RRB-
cord-302756-343y63e5	49	54	[	[	-LRB-
cord-302756-343y63e5	49	55	27	27	CD
cord-302756-343y63e5	49	56	]	]	-RRB-
cord-302756-343y63e5	49	57	.	.	.
cord-302756-343y63e5	50	1	It	-PRON-	PRP
cord-302756-343y63e5	50	2	would	would	MD
cord-302756-343y63e5	50	3	be	be	VB
cord-302756-343y63e5	50	4	ideal	ideal	JJ
cord-302756-343y63e5	50	5	in	in	IN
cord-302756-343y63e5	50	6	these	these	DT
cord-302756-343y63e5	50	7	situations	situation	NNS
cord-302756-343y63e5	50	8	This	this	DT
cord-302756-343y63e5	50	9	article	article	NN
cord-302756-343y63e5	50	10	is	be	VBZ
cord-302756-343y63e5	50	11	protected	protect	VBN
cord-302756-343y63e5	50	12	by	by	IN
cord-302756-343y63e5	50	13	copyright	copyright	NN
cord-302756-343y63e5	50	14	.	.	.
cord-302756-343y63e5	51	1	All	all	DT
cord-302756-343y63e5	51	2	rights	right	NNS
cord-302756-343y63e5	51	3	reserved	reserve	VBN
cord-302756-343y63e5	51	4	to	to	TO
cord-302756-343y63e5	51	5	depend	depend	VB
cord-302756-343y63e5	51	6	on	on	IN
cord-302756-343y63e5	51	7	laboratory	laboratory	NN
cord-302756-343y63e5	51	8	markers	marker	NNS
cord-302756-343y63e5	51	9	which	which	WDT
cord-302756-343y63e5	51	10	can	can	MD
cord-302756-343y63e5	51	11	predict	predict	VB
cord-302756-343y63e5	51	12	the	the	DT
cord-302756-343y63e5	51	13	transition	transition	NN
cord-302756-343y63e5	51	14	from	from	IN
cord-302756-343y63e5	51	15	the	the	DT
cord-302756-343y63e5	51	16	beneficial	beneficial	JJ
cord-302756-343y63e5	51	17	pulmonary	pulmonary	JJ
cord-302756-343y63e5	51	18	coagulation	coagulation	NN
cord-302756-343y63e5	51	19	activation	activation	NN
cord-302756-343y63e5	51	20	to	to	IN
cord-302756-343y63e5	51	21	harmful	harmful	JJ
cord-302756-343y63e5	51	22	systemic	systemic	JJ
cord-302756-343y63e5	51	23	spread	spread	NN
cord-302756-343y63e5	51	24	.	.	.
cord-302756-343y63e5	52	1	Based	base	VBN
cord-302756-343y63e5	52	2	on	on	IN
cord-302756-343y63e5	52	3	the	the	DT
cord-302756-343y63e5	52	4	currently	currently	RB
cord-302756-343y63e5	52	5	available	available	JJ
cord-302756-343y63e5	52	6	laboratory	laboratory	NN
cord-302756-343y63e5	52	7	markers	marker	NNS
cord-302756-343y63e5	52	8	,	,	,
cord-302756-343y63e5	52	9	of	of	IN
cord-302756-343y63e5	52	10	which	which	WDT
cord-302756-343y63e5	52	11	D	d	NN
cord-302756-343y63e5	52	12	-	-	HYPH
cord-302756-343y63e5	52	13	dimers	dimer	NNS
cord-302756-343y63e5	52	14	seem	seem	VBP
cord-302756-343y63e5	52	15	to	to	TO
cord-302756-343y63e5	52	16	be	be	VB
cord-302756-343y63e5	52	17	the	the	DT
cord-302756-343y63e5	52	18	most	most	RBS
cord-302756-343y63e5	52	19	consistent	consistent	JJ
cord-302756-343y63e5	52	20	,	,	,
cord-302756-343y63e5	52	21	we	-PRON-	PRP
cord-302756-343y63e5	52	22	provide	provide	VBP
cord-302756-343y63e5	52	23	a	a	DT
cord-302756-343y63e5	52	24	suggested	suggest	VBN
cord-302756-343y63e5	52	25	approach	approach	NN
cord-302756-343y63e5	52	26	but	but	CC
cord-302756-343y63e5	52	27	stress	stress	NN
cord-302756-343y63e5	52	28	that	that	IN
cord-302756-343y63e5	52	29	this	this	DT
cord-302756-343y63e5	52	30	requires	require	VBZ
cord-302756-343y63e5	52	31	confirmation	confirmation	NN
cord-302756-343y63e5	52	32	from	from	IN
cord-302756-343y63e5	52	33	ongoing	ongoing	JJ
cord-302756-343y63e5	52	34	trials	trial	NNS
cord-302756-343y63e5	52	35	(	(	-LRB-
cord-302756-343y63e5	52	36	Fig	Fig	NNP
cord-302756-343y63e5	52	37	.	.	NNP
cord-302756-343y63e5	52	38	1	1	CD
cord-302756-343y63e5	52	39	)	)	-RRB-
cord-302756-343y63e5	52	40	.	.	.
cord-302756-343y63e5	53	1	When	when	WRB
cord-302756-343y63e5	53	2	the	the	DT
cord-302756-343y63e5	53	3	patient	patient	NN
cord-302756-343y63e5	53	4	presents	present	VBZ
cord-302756-343y63e5	53	5	to	to	IN
cord-302756-343y63e5	53	6	the	the	DT
cord-302756-343y63e5	53	7	hospital	hospital	NN
cord-302756-343y63e5	53	8	,	,	,
cord-302756-343y63e5	53	9	if	if	IN
cord-302756-343y63e5	53	10	the	the	DT
cord-302756-343y63e5	53	11	D	d	NN
cord-302756-343y63e5	53	12	-	-	HYPH
cord-302756-343y63e5	53	13	dimers	dimer	NNS
cord-302756-343y63e5	53	14	are	be	VBP
cord-302756-343y63e5	53	15	increased	increase	VBN
cord-302756-343y63e5	53	16	,	,	,
cord-302756-343y63e5	53	17	prophylactic	prophylactic	JJ
cord-302756-343y63e5	53	18	anticoagulation	anticoagulation	NN
cord-302756-343y63e5	53	19	with	with	IN
cord-302756-343y63e5	53	20	low	low	JJ
cord-302756-343y63e5	53	21	molecular	molecular	JJ
cord-302756-343y63e5	53	22	weight	weight	NN
cord-302756-343y63e5	53	23	heparin	heparin	NN
cord-302756-343y63e5	53	24	should	should	MD
cord-302756-343y63e5	53	25	be	be	VB
cord-302756-343y63e5	53	26	given	give	VBN
cord-302756-343y63e5	53	27	to	to	IN
cord-302756-343y63e5	53	28	all	all	DT
cord-302756-343y63e5	53	29	patients	patient	NNS
cord-302756-343y63e5	53	30	in	in	IN
cord-302756-343y63e5	53	31	the	the	DT
cord-302756-343y63e5	53	32	absence	absence	NN
cord-302756-343y63e5	53	33	of	of	IN
cord-302756-343y63e5	53	34	contraindications	contraindication	NNS
cord-302756-343y63e5	53	35	as	as	IN
cord-302756-343y63e5	53	36	per	per	IN
cord-302756-343y63e5	53	37	current	current	JJ
cord-302756-343y63e5	53	38	guidance	guidance	NN
cord-302756-343y63e5	53	39	documents	document	NNS
cord-302756-343y63e5	53	40	[	[	-LRB-
cord-302756-343y63e5	53	41	22	22	CD
cord-302756-343y63e5	53	42	,	,	,
cord-302756-343y63e5	53	43	23	23	CD
cord-302756-343y63e5	53	44	]	]	-RRB-
cord-302756-343y63e5	53	45	.	.	.
cord-302756-343y63e5	54	1	like	like	IN
cord-302756-343y63e5	54	2	antiplatelets	antiplatelet	NNS
cord-302756-343y63e5	54	3	and	and	CC
cord-302756-343y63e5	54	4	others	other	NNS
cord-302756-343y63e5	54	5	(	(	-LRB-
cord-302756-343y63e5	54	6	described	describe	VBN
cord-302756-343y63e5	54	7	above	above	RB
cord-302756-343y63e5	54	8	)	)	-RRB-
cord-302756-343y63e5	54	9	should	should	MD
cord-302756-343y63e5	54	10	be	be	VB
cord-302756-343y63e5	54	11	considered	consider	VBN
cord-302756-343y63e5	54	12	in	in	IN
cord-302756-343y63e5	54	13	a	a	DT
cord-302756-343y63e5	54	14	trial	trial	NN
cord-302756-343y63e5	54	15	setting	setting	NN
cord-302756-343y63e5	54	16	.	.	.
cord-302756-343y63e5	55	1	Thrombolysis	thrombolysis	NN
cord-302756-343y63e5	55	2	using	use	VBG
cord-302756-343y63e5	55	3	inhaled	inhale	VBN
cord-302756-343y63e5	55	4	or	or	CC
cord-302756-343y63e5	55	5	systemic	systemic	JJ
cord-302756-343y63e5	55	6	tissue	tissue	NN
cord-302756-343y63e5	55	7	plasminogen	plasminogen	NN
cord-302756-343y63e5	55	8	activator	activator	NN
cord-302756-343y63e5	55	9	has	have	VBZ
cord-302756-343y63e5	55	10	been	be	VBN
cord-302756-343y63e5	55	11	attempted	attempt	VBN
cord-302756-343y63e5	55	12	in	in	IN
cord-302756-343y63e5	55	13	some	some	DT
cord-302756-343y63e5	55	14	patients	patient	NNS
cord-302756-343y63e5	55	15	who	who	WP
cord-302756-343y63e5	55	16	worsen	worsen	VBP
cord-302756-343y63e5	55	17	despite	despite	IN
cord-302756-343y63e5	55	18	therapeutic	therapeutic	JJ
cord-302756-343y63e5	55	19	anticoagulation	anticoagulation	NN
cord-302756-343y63e5	55	20	and	and	CC
cord-302756-343y63e5	55	21	maximal	maximal	JJ
cord-302756-343y63e5	55	22	critical	critical	JJ
cord-302756-343y63e5	55	23	care	care	NN
cord-302756-343y63e5	55	24	support	support	NN
cord-302756-343y63e5	55	25	[	[	-LRB-
cord-302756-343y63e5	55	26	27	27	CD
cord-302756-343y63e5	55	27	]	]	-RRB-
cord-302756-343y63e5	55	28	.	.	.
cord-302756-343y63e5	56	1	Regarding	regard	VBG
cord-302756-343y63e5	56	2	anticoagulation	anticoagulation	NN
cord-302756-343y63e5	56	3	,	,	,
cord-302756-343y63e5	56	4	the	the	DT
cord-302756-343y63e5	56	5	drug	drug	NN
cord-302756-343y63e5	56	6	of	of	IN
cord-302756-343y63e5	56	7	choice	choice	NN
cord-302756-343y63e5	56	8	is	be	VBZ
cord-302756-343y63e5	56	9	low	low	JJ
cord-302756-343y63e5	56	10	molecular	molecular	JJ
cord-302756-343y63e5	56	11	weight	weight	NN
cord-302756-343y63e5	56	12	heparin	heparin	NN
cord-302756-343y63e5	56	13	due	due	IN
cord-302756-343y63e5	56	14	to	to	IN
cord-302756-343y63e5	56	15	better	well	JJR
cord-302756-343y63e5	56	16	bioavailability	bioavailability	NN
cord-302756-343y63e5	56	17	and	and	CC
cord-302756-343y63e5	56	18	ease	ease	NN
cord-302756-343y63e5	56	19	of	of	IN
cord-302756-343y63e5	56	20	use	use	NN
cord-302756-343y63e5	56	21	.	.	.
cord-302756-343y63e5	57	1	However	however	RB
cord-302756-343y63e5	57	2	,	,	,
cord-302756-343y63e5	57	3	in	in	IN
cord-302756-343y63e5	57	4	patients	patient	NNS
cord-302756-343y63e5	57	5	who	who	WP
cord-302756-343y63e5	57	6	may	may	MD
cord-302756-343y63e5	57	7	have	have	VB
cord-302756-343y63e5	57	8	severe	severe	JJ
cord-302756-343y63e5	57	9	renal	renal	JJ
cord-302756-343y63e5	57	10	impairment	impairment	NN
cord-302756-343y63e5	57	11	or	or	CC
cord-302756-343y63e5	57	12	extremely	extremely	RB
cord-302756-343y63e5	57	13	high	high	JJ
cord-302756-343y63e5	57	14	risk	risk	NN
cord-302756-343y63e5	57	15	of	of	IN
cord-302756-343y63e5	57	16	bleeding	bleed	VBG
cord-302756-343y63e5	57	17	,	,	,
cord-302756-343y63e5	57	18	unfractionated	unfractionated	JJ
cord-302756-343y63e5	57	19	heparin	heparin	NN
cord-302756-343y63e5	57	20	may	may	MD
cord-302756-343y63e5	57	21	be	be	VB
cord-302756-343y63e5	57	22	considered	consider	VBN
cord-302756-343y63e5	57	23	.	.	.
cord-302756-343y63e5	58	1	Some	some	DT
cord-302756-343y63e5	58	2	early	early	JJ
cord-302756-343y63e5	58	3	reports	report	NNS
cord-302756-343y63e5	58	4	suggest	suggest	VBP
cord-302756-343y63e5	58	5	that	that	DT
cord-302756-343y63e5	58	6	point	point	NN
cord-302756-343y63e5	58	7	of	of	IN
cord-302756-343y63e5	58	8	care	care	NN
cord-302756-343y63e5	58	9	viscoelastic	viscoelastic	JJ
cord-302756-343y63e5	58	10	tests	test	NNS
cord-302756-343y63e5	58	11	such	such	JJ
cord-302756-343y63e5	58	12	as	as	IN
cord-302756-343y63e5	58	13	thrombo	thrombo	NN
cord-302756-343y63e5	58	14	-	-	HYPH
cord-302756-343y63e5	58	15	elastography	elastography	NN
cord-302756-343y63e5	58	16	(	(	-LRB-
cord-302756-343y63e5	58	17	TEG	TEG	NNP
cord-302756-343y63e5	58	18	)	)	-RRB-
cord-302756-343y63e5	58	19	or	or	CC
cord-302756-343y63e5	58	20	rotational	rotational	JJ
cord-302756-343y63e5	58	21	thrombo	thrombo	NNP
cord-302756-343y63e5	58	22	-	-	HYPH
cord-302756-343y63e5	58	23	elastometry	elastometry	NNP
cord-302756-343y63e5	58	24	(	(	-LRB-
cord-302756-343y63e5	58	25	ROTEM	ROTEM	NNP
cord-302756-343y63e5	58	26	)	)	-RRB-
cord-302756-343y63e5	58	27	may	may	MD
cord-302756-343y63e5	58	28	be	be	VB
cord-302756-343y63e5	58	29	helpful	helpful	JJ
cord-302756-343y63e5	58	30	in	in	IN
cord-302756-343y63e5	58	31	guiding	guide	VBG
cord-302756-343y63e5	58	32	treatment	treatment	NN
cord-302756-343y63e5	58	33	.	.	.
cord-302756-343y63e5	59	1	Data	datum	NNS
cord-302756-343y63e5	59	2	from	from	IN
cord-302756-343y63e5	59	3	observational	observational	JJ
cord-302756-343y63e5	59	4	studies	study	NNS
cord-302756-343y63e5	59	5	has	have	VBZ
cord-302756-343y63e5	59	6	shown	show	VBN
cord-302756-343y63e5	59	7	evidence	evidence	NN
cord-302756-343y63e5	59	8	of	of	IN
cord-302756-343y63e5	59	9	hypercoagulability	hypercoagulability	NN
cord-302756-343y63e5	59	10	on	on	IN
cord-302756-343y63e5	59	11	TEG	TEG	NNP
cord-302756-343y63e5	59	12	with	with	IN
cord-302756-343y63e5	59	13	decreased	decrease	VBN
cord-302756-343y63e5	59	14	'	'	``
cord-302756-343y63e5	59	15	r	r	NN
cord-302756-343y63e5	59	16	'	'	''
cord-302756-343y63e5	59	17	and	and	CC
cord-302756-343y63e5	59	18	'	'	``
cord-302756-343y63e5	59	19	k	k	XX
cord-302756-343y63e5	59	20	'	'	CC
cord-302756-343y63e5	59	21	times	time	NNS
cord-302756-343y63e5	59	22	and	and	CC
cord-302756-343y63e5	59	23	increased	increase	VBN
cord-302756-343y63e5	59	24	maximum	maximum	JJ
cord-302756-343y63e5	59	25	amplitudes	amplitude	NNS
cord-302756-343y63e5	59	26	(	(	-LRB-
cord-302756-343y63e5	59	27	MA	MA	NNP
cord-302756-343y63e5	59	28	)	)	-RRB-
cord-302756-343y63e5	59	29	in	in	IN
cord-302756-343y63e5	59	30	patients	patient	NNS
cord-302756-343y63e5	59	31	with	with	IN
cord-302756-343y63e5	59	32	known	know	VBN
cord-302756-343y63e5	59	33	raised	raise	VBN
cord-302756-343y63e5	59	34	fibrinogen	fibrinogen	NN
cord-302756-343y63e5	59	35	and	and	CC
cord-302756-343y63e5	59	36	Ddimer	Ddimer	NNP
cord-302756-343y63e5	59	37	levels	level	NNS
cord-302756-343y63e5	59	38	[	[	-LRB-
cord-302756-343y63e5	59	39	29	29	CD
cord-302756-343y63e5	59	40	]	]	-RRB-
cord-302756-343y63e5	60	1	This	this	DT
cord-302756-343y63e5	60	2	was	be	VBD
cord-302756-343y63e5	60	3	also	also	RB
cord-302756-343y63e5	60	4	demonstrated	demonstrate	VBN
cord-302756-343y63e5	60	5	with	with	IN
cord-302756-343y63e5	60	6	the	the	DT
cord-302756-343y63e5	60	7	ROTEM	ROTEM	NNP
cord-302756-343y63e5	60	8	with	with	IN
cord-302756-343y63e5	60	9	a	a	DT
cord-302756-343y63e5	60	10	shorter	short	JJR
cord-302756-343y63e5	60	11	clot	clot	NN
cord-302756-343y63e5	60	12	formation	formation	NN
cord-302756-343y63e5	60	13	time	time	NN
cord-302756-343y63e5	60	14	and	and	CC
cord-302756-343y63e5	60	15	high	high	JJ
cord-302756-343y63e5	60	16	clot	clot	NN
cord-302756-343y63e5	60	17	firmness	firmness	NN
cord-302756-343y63e5	60	18	[	[	-LRB-
cord-302756-343y63e5	60	19	30	30	CD
cord-302756-343y63e5	60	20	]	]	-RRB-
cord-302756-343y63e5	60	21	.	.	.
cord-302756-343y63e5	61	1	A	a	DT
cord-302756-343y63e5	61	2	separate	separate	JJ
cord-302756-343y63e5	61	3	study	study	NN
cord-302756-343y63e5	61	4	using	use	VBG
cord-302756-343y63e5	61	5	the	the	DT
cord-302756-343y63e5	61	6	Quantra	Quantra	NNP
cord-302756-343y63e5	61	7	(	(	-LRB-
cord-302756-343y63e5	61	8	Hemosonics	Hemosonics	NNP
cord-302756-343y63e5	61	9	,	,	,
cord-302756-343y63e5	61	10	Charlottesville	Charlottesville	NNP
cord-302756-343y63e5	61	11	,	,	,
cord-302756-343y63e5	61	12	VA	VA	NNP
cord-302756-343y63e5	61	13	,	,	,
cord-302756-343y63e5	61	14	USA	USA	NNP
cord-302756-343y63e5	61	15	)	)	-RRB-
cord-302756-343y63e5	61	16	again	again	RB
cord-302756-343y63e5	61	17	demonstrated	demonstrate	VBD
cord-302756-343y63e5	61	18	a	a	DT
cord-302756-343y63e5	61	19	procoagulant	procoagulant	NN
cord-302756-343y63e5	61	20	profile	profile	NN
cord-302756-343y63e5	61	21	with	with	IN
cord-302756-343y63e5	61	22	increased	increase	VBN
cord-302756-343y63e5	61	23	clot	clot	NN
cord-302756-343y63e5	61	24	strength	strength	NN
cord-302756-343y63e5	61	25	,	,	,
cord-302756-343y63e5	61	26	increased	increase	VBN
cord-302756-343y63e5	61	27	platelet	platelet	NN
cord-302756-343y63e5	61	28	and	and	CC
cord-302756-343y63e5	61	29	fibrinogen	fibrinogen	NN
cord-302756-343y63e5	61	30	contributions	contribution	NNS
cord-302756-343y63e5	61	31	in	in	IN
cord-302756-343y63e5	61	32	patients	patient	NNS
cord-302756-343y63e5	61	33	with	with	IN
cord-302756-343y63e5	61	34	known	known	JJ
cord-302756-343y63e5	61	35	elevated	elevated	JJ
cord-302756-343y63e5	61	36	D	d	NN
cord-302756-343y63e5	61	37	-	-	HYPH
cord-302756-343y63e5	61	38	dimer	dimer	NN
cord-302756-343y63e5	61	39	and	and	CC
cord-302756-343y63e5	61	40	fibrinogen	fibrinogen	NN
cord-302756-343y63e5	61	41	levels	level	NNS
cord-302756-343y63e5	61	42	[	[	-LRB-
cord-302756-343y63e5	61	43	24	24	CD
cord-302756-343y63e5	61	44	]	]	-RRB-
cord-302756-343y63e5	61	45	.	.	.
cord-302756-343y63e5	62	1	It	-PRON-	PRP
cord-302756-343y63e5	62	2	may	may	MD
cord-302756-343y63e5	62	3	be	be	VB
cord-302756-343y63e5	62	4	that	that	IN
cord-302756-343y63e5	62	5	those	those	DT
cord-302756-343y63e5	62	6	with	with	IN
cord-302756-343y63e5	62	7	greater	great	JJR
cord-302756-343y63e5	62	8	hypercoagulability	hypercoagulability	NN
cord-302756-343y63e5	62	9	have	have	VBP
cord-302756-343y63e5	62	10	a	a	DT
cord-302756-343y63e5	62	11	worse	bad	JJR
cord-302756-343y63e5	62	12	outcome	outcome	NN
cord-302756-343y63e5	62	13	.	.	.
cord-302756-343y63e5	63	1	In	in	IN
cord-302756-343y63e5	63	2	addition	addition	NN
cord-302756-343y63e5	63	3	,	,	,
cord-302756-343y63e5	63	4	there	there	EX
cord-302756-343y63e5	63	5	may	may	MD
cord-302756-343y63e5	63	6	be	be	VB
cord-302756-343y63e5	63	7	a	a	DT
cord-302756-343y63e5	63	8	possibility	possibility	NN
cord-302756-343y63e5	63	9	of	of	IN
cord-302756-343y63e5	63	10	using	use	VBG
cord-302756-343y63e5	63	11	one	one	CD
cord-302756-343y63e5	63	12	of	of	IN
cord-302756-343y63e5	63	13	these	these	DT
cord-302756-343y63e5	63	14	point	point	NN
cord-302756-343y63e5	63	15	of	of	IN
cord-302756-343y63e5	63	16	care	care	NN
cord-302756-343y63e5	63	17	viscoelastic	viscoelastic	JJ
cord-302756-343y63e5	63	18	tests	test	NNS
cord-302756-343y63e5	63	19	as	as	IN
cord-302756-343y63e5	63	20	a	a	DT
cord-302756-343y63e5	63	21	screening	screening	NN
cord-302756-343y63e5	63	22	tool	tool	NN
cord-302756-343y63e5	63	23	.	.	.
cord-302756-343y63e5	64	1	although	although	IN
cord-302756-343y63e5	64	2	this	this	DT
cord-302756-343y63e5	64	3	requires	require	VBZ
cord-302756-343y63e5	64	4	a	a	DT
cord-302756-343y63e5	64	5	great	great	JJ
cord-302756-343y63e5	64	6	deal	deal	NN
cord-302756-343y63e5	64	7	of	of	IN
cord-302756-343y63e5	64	8	further	further	JJ
cord-302756-343y63e5	64	9	research	research	NN
cord-302756-343y63e5	64	10	.	.	.
cord-302756-343y63e5	65	1	It	-PRON-	PRP
cord-302756-343y63e5	65	2	may	may	MD
cord-302756-343y63e5	65	3	also	also	RB
cord-302756-343y63e5	65	4	be	be	VB
cord-302756-343y63e5	65	5	that	that	IN
cord-302756-343y63e5	65	6	these	these	DT
cord-302756-343y63e5	65	7	tests	test	NNS
cord-302756-343y63e5	65	8	can	can	MD
cord-302756-343y63e5	65	9	be	be	VB
cord-302756-343y63e5	65	10	used	use	VBN
cord-302756-343y63e5	65	11	optimise	optimise	VB
cord-302756-343y63e5	65	12	This	this	DT
cord-302756-343y63e5	65	13	article	article	NN
cord-302756-343y63e5	65	14	is	be	VBZ
cord-302756-343y63e5	65	15	protected	protect	VBN
cord-302756-343y63e5	65	16	by	by	IN
cord-302756-343y63e5	65	17	copyright	copyright	NN
cord-302756-343y63e5	65	18	.	.	.
cord-302756-343y63e5	66	1	All	all	DT
cord-302756-343y63e5	66	2	rights	right	NNS
cord-302756-343y63e5	66	3	reserved	reserve	VBN
cord-302756-343y63e5	66	4	anticoagulation	anticoagulation	NN
cord-302756-343y63e5	66	5	therapy	therapy	NN
cord-302756-343y63e5	66	6	,	,	,
cord-302756-343y63e5	66	7	particularly	particularly	RB
cord-302756-343y63e5	66	8	in	in	IN
cord-302756-343y63e5	66	9	the	the	DT
cord-302756-343y63e5	66	10	acute	acute	JJ
cord-302756-343y63e5	66	11	ICU	ICU	NNP
cord-302756-343y63e5	66	12	setting	setting	NN
cord-302756-343y63e5	66	13	,	,	,
cord-302756-343y63e5	66	14	although	although	IN
cord-302756-343y63e5	66	15	this	this	DT
cord-302756-343y63e5	66	16	again	again	RB
cord-302756-343y63e5	66	17	needs	need	VBZ
cord-302756-343y63e5	66	18	further	further	JJ
cord-302756-343y63e5	66	19	research	research	NN
cord-302756-343y63e5	66	20	.	.	.
cord-302756-343y63e5	67	1	Overt	overt	JJ
cord-302756-343y63e5	67	2	bleeding	bleeding	NN
cord-302756-343y63e5	67	3	is	be	VBZ
cord-302756-343y63e5	67	4	rare	rare	JJ
cord-302756-343y63e5	67	5	in	in	IN
cord-302756-343y63e5	67	6	COVID-19	covid-19	JJ
cord-302756-343y63e5	67	7	patients	patient	NNS
cord-302756-343y63e5	67	8	although	although	IN
cord-302756-343y63e5	67	9	there	there	EX
cord-302756-343y63e5	67	10	are	be	VBP
cord-302756-343y63e5	67	11	patients	patient	NNS
cord-302756-343y63e5	67	12	who	who	WP
cord-302756-343y63e5	67	13	develop	develop	VBP
cord-302756-343y63e5	67	14	disseminated	disseminate	VBN
cord-302756-343y63e5	67	15	intravascular	intravascular	JJ
cord-302756-343y63e5	67	16	coagulation	coagulation	NN
cord-302756-343y63e5	67	17	(	(	-LRB-
cord-302756-343y63e5	67	18	DIC	DIC	NNP
cord-302756-343y63e5	67	19	)	)	-RRB-
cord-302756-343y63e5	67	20	in	in	IN
cord-302756-343y63e5	67	21	common	common	JJ
cord-302756-343y63e5	67	22	with	with	IN
cord-302756-343y63e5	67	23	many	many	JJ
cord-302756-343y63e5	67	24	patients	patient	NNS
cord-302756-343y63e5	67	25	who	who	WP
cord-302756-343y63e5	67	26	are	be	VBP
cord-302756-343y63e5	67	27	critically	critically	RB
cord-302756-343y63e5	67	28	unwell	unwell	JJ
cord-302756-343y63e5	67	29	.	.	.
cord-302756-343y63e5	68	1	However	however	RB
cord-302756-343y63e5	68	2	,	,	,
cord-302756-343y63e5	68	3	heparinisation	heparinisation	NN
cord-302756-343y63e5	68	4	may	may	MD
cord-302756-343y63e5	68	5	be	be	VB
cord-302756-343y63e5	68	6	difficult	difficult	JJ
cord-302756-343y63e5	68	7	to	to	TO
cord-302756-343y63e5	68	8	manage	manage	VB
cord-302756-343y63e5	68	9	.	.	.
cord-302756-343y63e5	69	1	Helms	Helms	NNP
cord-302756-343y63e5	69	2	et	et	NNP
cord-302756-343y63e5	69	3	al	al	NNP
cord-302756-343y63e5	69	4	.	.	.
cord-302756-343y63e5	70	1	recently	recently	RB
cord-302756-343y63e5	70	2	reported	report	VBD
cord-302756-343y63e5	70	3	that	that	IN
cord-302756-343y63e5	70	4	96.6	96.6	CD
cord-302756-343y63e5	70	5	%	%	NN
cord-302756-343y63e5	70	6	of	of	IN
cord-302756-343y63e5	70	7	patients	patient	NNS
cord-302756-343y63e5	70	8	requiring	require	VBG
cord-302756-343y63e5	70	9	renal	renal	JJ
cord-302756-343y63e5	70	10	replacement	replacement	NN
cord-302756-343y63e5	70	11	therapy	therapy	NN
cord-302756-343y63e5	70	12	experienced	experience	VBD
cord-302756-343y63e5	70	13	circuit	circuit	NN
cord-302756-343y63e5	70	14	clotting	clotting	NN
cord-302756-343y63e5	70	15	,	,	,
cord-302756-343y63e5	70	16	and	and	CC
cord-302756-343y63e5	70	17	in	in	IN
cord-302756-343y63e5	70	18	twelve	twelve	CD
cord-302756-343y63e5	70	19	patients	patient	NNS
cord-302756-343y63e5	70	20	requiring	require	VBG
cord-302756-343y63e5	70	21	extracorporeal	extracorporeal	JJ
cord-302756-343y63e5	70	22	membrane	membrane	NN
cord-302756-343y63e5	70	23	oxygenation	oxygenation	NN
cord-302756-343y63e5	70	24	(	(	-LRB-
cord-302756-343y63e5	70	25	ECMO	ECMO	NNP
cord-302756-343y63e5	70	26	)	)	-RRB-
cord-302756-343y63e5	70	27	,	,	,
cord-302756-343y63e5	70	28	there	there	EX
cord-302756-343y63e5	70	29	were	be	VBD
cord-302756-343y63e5	70	30	three	three	CD
cord-302756-343y63e5	70	31	thrombotic	thrombotic	JJ
cord-302756-343y63e5	70	32	occlusions	occlusion	NNS
cord-302756-343y63e5	70	33	of	of	IN
cord-302756-343y63e5	70	34	the	the	DT
cord-302756-343y63e5	70	35	centrifugal	centrifugal	JJ
cord-302756-343y63e5	70	36	pump	pump	NN
cord-302756-343y63e5	70	37	(	(	-LRB-
cord-302756-343y63e5	70	38	in	in	IN
cord-302756-343y63e5	70	39	two	two	CD
cord-302756-343y63e5	70	40	patients	patient	NNS
cord-302756-343y63e5	70	41	)	)	-RRB-
cord-302756-343y63e5	70	42	requiring	require	VBG
cord-302756-343y63e5	70	43	prompt	prompt	JJ
cord-302756-343y63e5	70	44	pump	pump	NN
cord-302756-343y63e5	70	45	replacement	replacement	NN
cord-302756-343y63e5	70	46	[	[	-LRB-
cord-302756-343y63e5	70	47	31	31	CD
cord-302756-343y63e5	70	48	]	]	-RRB-
cord-302756-343y63e5	70	49	.	.	.
cord-302756-343y63e5	71	1	This	this	DT
cord-302756-343y63e5	71	2	is	be	VBZ
cord-302756-343y63e5	71	3	turn	turn	NN
cord-302756-343y63e5	71	4	may	may	MD
cord-302756-343y63e5	71	5	lead	lead	VB
cord-302756-343y63e5	71	6	the	the	DT
cord-302756-343y63e5	71	7	clinician	clinician	NN
cord-302756-343y63e5	71	8	to	to	TO
cord-302756-343y63e5	71	9	increase	increase	VB
cord-302756-343y63e5	71	10	heparin	heparin	JJ
cord-302756-343y63e5	71	11	therapy	therapy	NN
cord-302756-343y63e5	71	12	leading	lead	VBG
cord-302756-343y63e5	71	13	to	to	IN
cord-302756-343y63e5	71	14	iatrogenic	iatrogenic	JJ
cord-302756-343y63e5	71	15	bleeding	bleeding	NN
cord-302756-343y63e5	71	16	.	.	.
cord-302756-343y63e5	72	1	The	the	DT
cord-302756-343y63e5	72	2	same	same	JJ
cord-302756-343y63e5	72	3	authors	author	NNS
cord-302756-343y63e5	72	4	found	find	VBD
cord-302756-343y63e5	72	5	that	that	IN
cord-302756-343y63e5	72	6	50	50	CD
cord-302756-343y63e5	72	7	out	out	IN
cord-302756-343y63e5	72	8	of	of	IN
cord-302756-343y63e5	72	9	57	57	CD
cord-302756-343y63e5	72	10	patients	patient	NNS
cord-302756-343y63e5	72	11	tested	test	VBN
cord-302756-343y63e5	72	12	had	have	VBD
cord-302756-343y63e5	72	13	positive	positive	JJ
cord-302756-343y63e5	72	14	lupus	lupus	NN
cord-302756-343y63e5	72	15	anticoagulant	anticoagulant	JJ
cord-302756-343y63e5	72	16	.	.	.
cord-302756-343y63e5	73	1	Lupus	lupus	JJ
cord-302756-343y63e5	73	2	anticoagulant	anticoagulant	NN
cord-302756-343y63e5	73	3	is	be	VBZ
cord-302756-343y63e5	73	4	known	know	VBN
cord-302756-343y63e5	73	5	to	to	TO
cord-302756-343y63e5	73	6	prolong	prolong	VB
cord-302756-343y63e5	73	7	the	the	DT
cord-302756-343y63e5	73	8	actibated	actibate	VBN
cord-302756-343y63e5	73	9	partial	partial	JJ
cord-302756-343y63e5	73	10	thromboplastin	thromboplastin	NNP
cord-302756-343y63e5	73	11	time	time	NN
cord-302756-343y63e5	73	12	(	(	-LRB-
cord-302756-343y63e5	73	13	APTT	APTT	NNP
cord-302756-343y63e5	73	14	)	)	-RRB-
cord-302756-343y63e5	73	15	;	;	:
cord-302756-343y63e5	73	16	it	-PRON-	PRP
cord-302756-343y63e5	73	17	may	may	MD
cord-302756-343y63e5	73	18	be	be	VB
cord-302756-343y63e5	73	19	that	that	IN
cord-302756-343y63e5	73	20	using	use	VBG
cord-302756-343y63e5	73	21	the	the	DT
cord-302756-343y63e5	73	22	APTT	APTT	NNP
cord-302756-343y63e5	73	23	to	to	TO
cord-302756-343y63e5	73	24	guide	guide	VB
cord-302756-343y63e5	73	25	heparin	heparin	NN
cord-302756-343y63e5	73	26	therapy	therapy	NN
cord-302756-343y63e5	73	27	leads	lead	VBZ
cord-302756-343y63e5	73	28	to	to	IN
cord-302756-343y63e5	73	29	underdosing	underdose	VBG
cord-302756-343y63e5	73	30	,	,	,
cord-302756-343y63e5	73	31	leading	lead	VBG
cord-302756-343y63e5	73	32	to	to	IN
cord-302756-343y63e5	73	33	an	an	DT
cord-302756-343y63e5	73	34	increase	increase	NN
cord-302756-343y63e5	73	35	in	in	IN
cord-302756-343y63e5	73	36	thrombosis	thrombosis	NN
cord-302756-343y63e5	73	37	in	in	IN
cord-302756-343y63e5	73	38	artificial	artificial	JJ
cord-302756-343y63e5	73	39	circuits	circuit	NNS
cord-302756-343y63e5	73	40	.	.	.
cord-302756-343y63e5	74	1	Currently	currently	RB
cord-302756-343y63e5	74	2	,	,	,
cord-302756-343y63e5	74	3	the	the	DT
cord-302756-343y63e5	74	4	only	only	JJ
cord-302756-343y63e5	74	5	marker	marker	NN
cord-302756-343y63e5	74	6	for	for	IN
cord-302756-343y63e5	74	7	coagulation	coagulation	NN
cord-302756-343y63e5	74	8	activation	activation	NN
cord-302756-343y63e5	74	9	is	be	VBZ
cord-302756-343y63e5	74	10	markedly	markedly	RB
cord-302756-343y63e5	74	11	elevated	elevate	VBN
cord-302756-343y63e5	74	12	D	d	NN
cord-302756-343y63e5	74	13	-	-	HYPH
cord-302756-343y63e5	74	14	dimers	dimer	NNS
cord-302756-343y63e5	74	15	,	,	,
cord-302756-343y63e5	74	16	which	which	WDT
cord-302756-343y63e5	74	17	is	be	VBZ
cord-302756-343y63e5	74	18	not	not	RB
cord-302756-343y63e5	74	19	specific	specific	JJ
cord-302756-343y63e5	74	20	to	to	IN
cord-302756-343y63e5	74	21	systemic	systemic	JJ
cord-302756-343y63e5	74	22	coagulopathy	coagulopathy	NN
cord-302756-343y63e5	74	23	.	.	.
cord-302756-343y63e5	75	1	Since	since	IN
cord-302756-343y63e5	75	2	the	the	DT
cord-302756-343y63e5	75	3	vascular	vascular	JJ
cord-302756-343y63e5	75	4	endothelium	endothelium	NN
cord-302756-343y63e5	75	5	is	be	VBZ
cord-302756-343y63e5	75	6	at	at	IN
cord-302756-343y63e5	75	7	the	the	DT
cord-302756-343y63e5	75	8	interface	interface	NN
cord-302756-343y63e5	75	9	of	of	IN
cord-302756-343y63e5	75	10	coagulation	coagulation	NN
cord-302756-343y63e5	75	11	and	and	CC
cord-302756-343y63e5	75	12	immune	immune	JJ
cord-302756-343y63e5	75	13	system	system	NN
cord-302756-343y63e5	75	14	(	(	-LRB-
cord-302756-343y63e5	75	15	recently	recently	RB
cord-302756-343y63e5	75	16	termed	term	VBN
cord-302756-343y63e5	75	17	as	as	IN
cord-302756-343y63e5	75	18	endothelilitis	endothelilitis	NNP
cord-302756-343y63e5	75	19	)	)	-RRB-
cord-302756-343y63e5	75	20	,	,	,
cord-302756-343y63e5	75	21	markers	marker	NNS
cord-302756-343y63e5	75	22	of	of	IN
cord-302756-343y63e5	75	23	endothelial	endothelial	JJ
cord-302756-343y63e5	75	24	activation	activation	NN
cord-302756-343y63e5	75	25	would	would	MD
cord-302756-343y63e5	75	26	be	be	VB
cord-302756-343y63e5	75	27	an	an	DT
cord-302756-343y63e5	75	28	interesting	interesting	JJ
cord-302756-343y63e5	75	29	research	research	NN
cord-302756-343y63e5	75	30	area	area	NN
cord-302756-343y63e5	75	31	[	[	-LRB-
cord-302756-343y63e5	75	32	30	30	CD
cord-302756-343y63e5	75	33	,	,	,
cord-302756-343y63e5	75	34	32	32	CD
cord-302756-343y63e5	75	35	]	]	-RRB-
cord-302756-343y63e5	75	36	.	.	.
cord-302756-343y63e5	76	1	Ruan	Ruan	NNP
cord-302756-343y63e5	76	2	et	et	NNP
cord-302756-343y63e5	76	3	al	al	NNP
cord-302756-343y63e5	76	4	.	.	.
cord-302756-343y63e5	77	1	showed	show	VBD
cord-302756-343y63e5	77	2	that	that	IN
cord-302756-343y63e5	77	3	interleukin-6	interleukin-6	NNP
cord-302756-343y63e5	77	4	concentrations	concentration	NNS
cord-302756-343y63e5	77	5	differed	differ	VBD
cord-302756-343y63e5	77	6	significantly	significantly	RB
cord-302756-343y63e5	77	7	in	in	IN
cord-302756-343y63e5	77	8	survivors	survivor	NNS
cord-302756-343y63e5	77	9	and	and	CC
cord-302756-343y63e5	77	10	non	non	NNS
cord-302756-343y63e5	77	11	-	-	NNS
cord-302756-343y63e5	77	12	survivors	survivor	NNS
cord-302756-343y63e5	77	13	of	of	IN
cord-302756-343y63e5	77	14	COVID-19	COVID-19	NNP
cord-302756-343y63e5	77	15	,	,	,
cord-302756-343y63e5	77	16	with	with	IN
cord-302756-343y63e5	77	17	non	non	NNS
cord-302756-343y63e5	77	18	-	-	NNS
cord-302756-343y63e5	77	19	survivors	survivor	NNS
cord-302756-343y63e5	77	20	having	have	VBG
cord-302756-343y63e5	77	21	almost	almost	RB
cord-302756-343y63e5	77	22	double	double	JJ
cord-302756-343y63e5	77	23	the	the	DT
cord-302756-343y63e5	77	24	level	level	NN
cord-302756-343y63e5	77	25	as	as	IN
cord-302756-343y63e5	77	26	survivors	survivor	NNS
cord-302756-343y63e5	77	27	[	[	-LRB-
cord-302756-343y63e5	77	28	33	33	CD
cord-302756-343y63e5	77	29	]	]	-RRB-
cord-302756-343y63e5	77	30	.	.	.
cord-302756-343y63e5	78	1	Ranucci	Ranucci	NNP
cord-302756-343y63e5	78	2	et	et	NNP
cord-302756-343y63e5	78	3	al	al	NNP
cord-302756-343y63e5	78	4	.	.	.
cord-302756-343y63e5	79	1	,	,	,
cord-302756-343y63e5	79	2	discussing	discuss	VBG
cord-302756-343y63e5	79	3	16	16	CD
cord-302756-343y63e5	79	4	patients	patient	NNS
cord-302756-343y63e5	79	5	with	with	IN
cord-302756-343y63e5	79	6	COVID-19	COVID-19	NNP
cord-302756-343y63e5	79	7	who	who	WP
cord-302756-343y63e5	79	8	required	require	VBD
cord-302756-343y63e5	79	9	mechanical	mechanical	JJ
cord-302756-343y63e5	79	10	ventilation	ventilation	NN
cord-302756-343y63e5	79	11	,	,	,
cord-302756-343y63e5	79	12	found	find	VBD
cord-302756-343y63e5	79	13	an	an	DT
cord-302756-343y63e5	79	14	increase	increase	NN
cord-302756-343y63e5	79	15	in	in	IN
cord-302756-343y63e5	79	16	interleukin-6	interleukin-6	NNP
cord-302756-343y63e5	79	17	(	(	-LRB-
cord-302756-343y63e5	79	18	IL-6	IL-6	NNP
cord-302756-343y63e5	79	19	)	)	-RRB-
cord-302756-343y63e5	79	20	levels	level	NNS
cord-302756-343y63e5	79	21	,	,	,
cord-302756-343y63e5	79	22	which	which	WDT
cord-302756-343y63e5	79	23	correlated	correlate	VBD
cord-302756-343y63e5	79	24	with	with	IN
cord-302756-343y63e5	79	25	increased	increase	VBN
cord-302756-343y63e5	79	26	fibrinogen	fibrinogen	NN
cord-302756-343y63e5	79	27	levels	level	NNS
cord-302756-343y63e5	79	28	,	,	,
cord-302756-343y63e5	79	29	confirming	confirm	VBG
cord-302756-343y63e5	79	30	the	the	DT
cord-302756-343y63e5	79	31	link	link	NN
cord-302756-343y63e5	79	32	between	between	IN
cord-302756-343y63e5	79	33	inflammation	inflammation	NN
cord-302756-343y63e5	79	34	and	and	CC
cord-302756-343y63e5	79	35	a	a	DT
cord-302756-343y63e5	79	36	procoagulant	procoagulant	JJ
cord-302756-343y63e5	79	37	state	state	NN
cord-302756-343y63e5	79	38	[	[	-LRB-
cord-302756-343y63e5	79	39	24	24	CD
cord-302756-343y63e5	79	40	]	]	-RRB-
cord-302756-343y63e5	79	41	.	.	.
cord-302756-343y63e5	80	1	It	-PRON-	PRP
cord-302756-343y63e5	80	2	is	be	VBZ
cord-302756-343y63e5	80	3	vital	vital	JJ
cord-302756-343y63e5	80	4	that	that	IN
cord-302756-343y63e5	80	5	healthcare	healthcare	NN
cord-302756-343y63e5	80	6	workers	worker	NNS
cord-302756-343y63e5	80	7	who	who	WP
cord-302756-343y63e5	80	8	deal	deal	VBP
cord-302756-343y63e5	80	9	with	with	IN
cord-302756-343y63e5	80	10	patients	patient	NNS
cord-302756-343y63e5	80	11	suffering	suffer	VBG
cord-302756-343y63e5	80	12	from	from	IN
cord-302756-343y63e5	80	13	COVID-19	COVID-19	NNP
cord-302756-343y63e5	80	14	are	be	VBP
cord-302756-343y63e5	80	15	familiar	familiar	JJ
cord-302756-343y63e5	80	16	with	with	IN
cord-302756-343y63e5	80	17	the	the	DT
cord-302756-343y63e5	80	18	spectrum	spectrum	NN
cord-302756-343y63e5	80	19	of	of	IN
cord-302756-343y63e5	80	20	coagulopathy	coagulopathy	NN
cord-302756-343y63e5	80	21	in	in	IN
cord-302756-343y63e5	80	22	this	this	DT
cord-302756-343y63e5	80	23	disease	disease	NN
cord-302756-343y63e5	80	24	.	.	.
cord-302756-343y63e5	81	1	However	however	RB
cord-302756-343y63e5	81	2	,	,	,
cord-302756-343y63e5	81	3	there	there	EX
cord-302756-343y63e5	81	4	remain	remain	VBP
cord-302756-343y63e5	81	5	many	many	JJ
cord-302756-343y63e5	81	6	questions	question	NNS
cord-302756-343y63e5	81	7	which	which	WDT
cord-302756-343y63e5	81	8	need	need	VBP
cord-302756-343y63e5	81	9	to	to	TO
cord-302756-343y63e5	81	10	be	be	VB
cord-302756-343y63e5	81	11	answered	answer	VBN
cord-302756-343y63e5	81	12	.	.	.
cord-302756-343y63e5	82	1	These	these	DT
cord-302756-343y63e5	82	2	include	include	VBP
cord-302756-343y63e5	82	3	:	:	:
cord-302756-343y63e5	82	4	should	should	MD
cord-302756-343y63e5	82	5	all	all	DT
cord-302756-343y63e5	82	6	patients	patient	NNS
cord-302756-343y63e5	82	7	hospitalised	hospitalise	VBN
cord-302756-343y63e5	82	8	with	with	IN
cord-302756-343y63e5	82	9	severe	severe	JJ
cord-302756-343y63e5	82	10	COVID-19	COVID-19	NNP
cord-302756-343y63e5	82	11	be	be	VB
cord-302756-343y63e5	82	12	treated	treat	VBN
cord-302756-343y63e5	82	13	empirically	empirically	RB
cord-302756-343y63e5	82	14	with	with	IN
cord-302756-343y63e5	82	15	therapeutic	therapeutic	JJ
cord-302756-343y63e5	82	16	anticoagulation	anticoagulation	NN
cord-302756-343y63e5	82	17	until	until	IN
cord-302756-343y63e5	82	18	venous	venous	JJ
cord-302756-343y63e5	82	19	thromboembolism	thromboembolism	NN
cord-302756-343y63e5	82	20	is	be	VBZ
cord-302756-343y63e5	82	21	discounted	discount	VBN
cord-302756-343y63e5	82	22	?	?	.
cord-302756-343y63e5	83	1	How	how	WRB
cord-302756-343y63e5	83	2	should	should	MD
cord-302756-343y63e5	83	3	we	-PRON-	PRP
cord-302756-343y63e5	83	4	manage	manage	VB
cord-302756-343y63e5	83	5	antiocoagulation	antiocoagulation	NN
cord-302756-343y63e5	83	6	for	for	IN
cord-302756-343y63e5	83	7	these	these	DT
cord-302756-343y63e5	83	8	patients	patient	NNS
cord-302756-343y63e5	83	9	on	on	IN
cord-302756-343y63e5	83	10	ICU	ICU	NNP
cord-302756-343y63e5	83	11	for	for	IN
cord-302756-343y63e5	83	12	renal	renal	JJ
cord-302756-343y63e5	83	13	replacement	replacement	NN
cord-302756-343y63e5	83	14	therapy	therapy	NN
cord-302756-343y63e5	83	15	or	or	CC
cord-302756-343y63e5	83	16	ECMO	ECMO	NNP
cord-302756-343y63e5	83	17	?	?	.
cord-302756-343y63e5	84	1	And	and	CC
cord-302756-343y63e5	84	2	as	as	IN
cord-302756-343y63e5	84	3	we	-PRON-	PRP
cord-302756-343y63e5	84	4	restart	restart	VBP
cord-302756-343y63e5	84	5	semi	semi	JJ
cord-302756-343y63e5	84	6	-	-	JJ
cord-302756-343y63e5	84	7	elective	elective	JJ
cord-302756-343y63e5	84	8	surgery	surgery	NN
cord-302756-343y63e5	84	9	should	should	MD
cord-302756-343y63e5	84	10	we	-PRON-	PRP
cord-302756-343y63e5	84	11	give	give	VB
cord-302756-343y63e5	84	12	patients	patient	NNS
cord-302756-343y63e5	84	13	subsequently	subsequently	RB
cord-302756-343y63e5	84	14	found	find	VBD
cord-302756-343y63e5	84	15	to	to	TO
cord-302756-343y63e5	84	16	be	be	VB
cord-302756-343y63e5	84	17	COVID-19	COVID-19	NNP
cord-302756-343y63e5	84	18	positive	positive	JJ
cord-302756-343y63e5	84	19	additional	additional	JJ
cord-302756-343y63e5	84	20	thromboprophylaxis	thromboprophylaxis	NN
cord-302756-343y63e5	84	21	?	?	.
cord-302756-343y63e5	85	1	If	if	IN
cord-302756-343y63e5	85	2	so	so	RB
cord-302756-343y63e5	85	3	,	,	,
cord-302756-343y63e5	85	4	for	for	IN
cord-302756-343y63e5	85	5	how	how	WRB
cord-302756-343y63e5	85	6	long	long	JJ
cord-302756-343y63e5	85	7	,	,	,
cord-302756-343y63e5	85	8	when	when	WRB
cord-302756-343y63e5	85	9	do	do	VBP
cord-302756-343y63e5	85	10	we	-PRON-	PRP
cord-302756-343y63e5	85	11	think	think	VB
cord-302756-343y63e5	85	12	the	the	DT
cord-302756-343y63e5	85	13	additional	additional	JJ
cord-302756-343y63e5	85	14	risk	risk	NN
cord-302756-343y63e5	85	15	has	have	VBZ
cord-302756-343y63e5	85	16	passed	pass	VBN
cord-302756-343y63e5	85	17	?	?	.
cord-302756-343y63e5	86	1	At	at	IN
cord-302756-343y63e5	86	2	present	present	NN
cord-302756-343y63e5	86	3	we	-PRON-	PRP
cord-302756-343y63e5	86	4	simply	simply	RB
cord-302756-343y63e5	86	5	do	do	VBP
cord-302756-343y63e5	86	6	not	not	RB
cord-302756-343y63e5	86	7	have	have	VB
cord-302756-343y63e5	86	8	adequate	adequate	JJ
cord-302756-343y63e5	86	9	answers	answer	NNS
cord-302756-343y63e5	86	10	for	for	IN
cord-302756-343y63e5	86	11	these	these	DT
cord-302756-343y63e5	86	12	questions	question	NNS
cord-302756-343y63e5	86	13	.	.	.
cord-302756-343y63e5	86	14	.	.	.
cord-302756-343y63e5	87	1	This	this	DT
cord-302756-343y63e5	87	2	article	article	NN
cord-302756-343y63e5	87	3	is	be	VBZ
cord-302756-343y63e5	87	4	protected	protect	VBN
cord-302756-343y63e5	87	5	by	by	IN
cord-302756-343y63e5	87	6	copyright	copyright	NN
cord-302756-343y63e5	87	7	.	.	.
cord-302756-343y63e5	88	1	All	all	DT
cord-302756-343y63e5	88	2	rights	right	NNS
cord-302756-343y63e5	88	3	reserved	reserve	VBD
cord-302756-343y63e5	88	4	The	the	DT
cord-302756-343y63e5	88	5	pathogenesis	pathogenesis	NN
cord-302756-343y63e5	88	6	and	and	CC
cord-302756-343y63e5	88	7	treatment	treatment	NN
cord-302756-343y63e5	88	8	of	of	IN
cord-302756-343y63e5	88	9	the	the	DT
cord-302756-343y63e5	88	10	'	'	``
cord-302756-343y63e5	88	11	Cytokine	Cytokine	NNP
cord-302756-343y63e5	88	12	Storm	Storm	NNP
cord-302756-343y63e5	88	13	'	'	''
cord-302756-343y63e5	88	14	in	in	IN
cord-302756-343y63e5	88	15	COVID-19	COVID-19	NNP
cord-302756-343y63e5	88	16	The	the	DT
cord-302756-343y63e5	88	17	use	use	NN
cord-302756-343y63e5	88	18	of	of	IN
cord-302756-343y63e5	88	19	anti	anti	JJ
cord-302756-343y63e5	88	20	-	-	JJ
cord-302756-343y63e5	88	21	inflammatory	inflammatory	JJ
cord-302756-343y63e5	88	22	drugs	drug	NNS
cord-302756-343y63e5	88	23	in	in	IN
cord-302756-343y63e5	88	24	the	the	DT
cord-302756-343y63e5	88	25	treatment	treatment	NN
cord-302756-343y63e5	88	26	of	of	IN
cord-302756-343y63e5	88	27	people	people	NNS
cord-302756-343y63e5	88	28	with	with	IN
cord-302756-343y63e5	88	29	severe	severe	JJ
cord-302756-343y63e5	88	30	coronavirus	coronavirus	NN
cord-302756-343y63e5	88	31	disease	disease	NN
cord-302756-343y63e5	88	32	2019	2019	CD
cord-302756-343y63e5	88	33	(	(	-LRB-
cord-302756-343y63e5	88	34	COVID-19	COVID-19	NNP
cord-302756-343y63e5	88	35	)	)	-RRB-
cord-302756-343y63e5	88	36	:	:	:
cord-302756-343y63e5	88	37	the	the	DT
cord-302756-343y63e5	88	38	perspectives	perspective	NNS
cord-302756-343y63e5	88	39	of	of	IN
cord-302756-343y63e5	88	40	clinical	clinical	JJ
cord-302756-343y63e5	88	41	immunologists	immunologist	NNS
cord-302756-343y63e5	88	42	from	from	IN
cord-302756-343y63e5	88	43	China	China	NNP
cord-302756-343y63e5	88	44	High	high	JJ
cord-302756-343y63e5	88	45	incidence	incidence	NN
cord-302756-343y63e5	88	46	of	of	IN
cord-302756-343y63e5	88	47	venous	venous	JJ
cord-302756-343y63e5	88	48	thromboembolic	thromboembolic	JJ
cord-302756-343y63e5	88	49	events	event	NNS
cord-302756-343y63e5	88	50	in	in	IN
cord-302756-343y63e5	88	51	anticoagulated	anticoagulated	JJ
cord-302756-343y63e5	88	52	severe	severe	JJ
cord-302756-343y63e5	88	53	COVID-19	COVID-19	NNP
cord-302756-343y63e5	88	54	patients	patient	NNS
cord-302756-343y63e5	89	1	Anticoagulant	anticoagulant	JJ
cord-302756-343y63e5	89	2	treatment	treatment	NN
cord-302756-343y63e5	89	3	is	be	VBZ
cord-302756-343y63e5	89	4	associated	associate	VBN
cord-302756-343y63e5	89	5	with	with	IN
cord-302756-343y63e5	89	6	decreased	decrease	VBN
cord-302756-343y63e5	89	7	mortality	mortality	NN
cord-302756-343y63e5	89	8	in	in	IN
cord-302756-343y63e5	89	9	severe	severe	JJ
cord-302756-343y63e5	89	10	coronavirus	coronavirus	NN
cord-302756-343y63e5	89	11	disease	disease	NN
cord-302756-343y63e5	89	12	2019	2019	CD
cord-302756-343y63e5	89	13	patients	patient	NNS
cord-302756-343y63e5	89	14	with	with	IN
cord-302756-343y63e5	89	15	coagulopathy	coagulopathy	NN
cord-302756-343y63e5	89	16	Incidence	incidence	NN
cord-302756-343y63e5	89	17	of	of	IN
cord-302756-343y63e5	89	18	thrombotic	thrombotic	JJ
cord-302756-343y63e5	89	19	complications	complication	NNS
cord-302756-343y63e5	89	20	in	in	IN
cord-302756-343y63e5	89	21	critically	critically	RB
cord-302756-343y63e5	89	22	ill	ill	JJ
cord-302756-343y63e5	89	23	ICU	ICU	NNP
cord-302756-343y63e5	89	24	patients	patient	NNS
cord-302756-343y63e5	89	25	with	with	IN
cord-302756-343y63e5	89	26	COVID-19	covid-19	JJ
cord-302756-343y63e5	89	27	Prevalence	prevalence	NN
cord-302756-343y63e5	89	28	of	of	IN
cord-302756-343y63e5	89	29	venous	venous	JJ
cord-302756-343y63e5	89	30	thromboembolism	thromboembolism	NN
cord-302756-343y63e5	89	31	in	in	IN
cord-302756-343y63e5	89	32	patients	patient	NNS
cord-302756-343y63e5	89	33	with	with	IN
cord-302756-343y63e5	89	34	severe	severe	JJ
cord-302756-343y63e5	89	35	novel	novel	JJ
cord-302756-343y63e5	89	36	coronavirus	coronavirus	NN
cord-302756-343y63e5	89	37	pneumonia	pneumonia	NN
cord-302756-343y63e5	89	38	Abnormal	abnormal	JJ
cord-302756-343y63e5	89	39	coagulation	coagulation	NN
cord-302756-343y63e5	89	40	parameters	parameter	NNS
cord-302756-343y63e5	89	41	are	be	VBP
cord-302756-343y63e5	89	42	associated	associate	VBN
cord-302756-343y63e5	89	43	with	with	IN
cord-302756-343y63e5	89	44	poor	poor	JJ
cord-302756-343y63e5	89	45	prognosis	prognosis	NN
cord-302756-343y63e5	89	46	in	in	IN
cord-302756-343y63e5	89	47	patients	patient	NNS
cord-302756-343y63e5	89	48	with	with	IN
cord-302756-343y63e5	89	49	novel	novel	JJ
cord-302756-343y63e5	89	50	coronavirus	coronavirus	NN
cord-302756-343y63e5	89	51	pneumonia	pneumonia	NN
cord-302756-343y63e5	89	52	New	new	JJ
cord-302756-343y63e5	89	53	types	type	NNS
cord-302756-343y63e5	89	54	of	of	IN
cord-302756-343y63e5	89	55	clotting	clotting	NN
cord-302756-343y63e5	89	56	factors	factor	NNS
cord-302756-343y63e5	89	57	and	and	CC
cord-302756-343y63e5	89	58	defence	defence	NN
cord-302756-343y63e5	89	59	molecules	molecule	NNS
cord-302756-343y63e5	89	60	found	find	VBN
cord-302756-343y63e5	89	61	in	in	IN
cord-302756-343y63e5	89	62	horseshoe	horseshoe	NNP
cord-302756-343y63e5	89	63	crab	crab	NNP
cord-302756-343y63e5	89	64	hemolymph	hemolymph	NNP
cord-302756-343y63e5	89	65	:	:	:
cord-302756-343y63e5	89	66	their	-PRON-	PRP$
cord-302756-343y63e5	89	67	structures	structure	NNS
cord-302756-343y63e5	89	68	and	and	CC
cord-302756-343y63e5	89	69	functions	function	NNS
cord-302756-343y63e5	89	70	Thrombosis	Thrombosis	NNP
cord-302756-343y63e5	89	71	as	as	IN
cord-302756-343y63e5	89	72	an	an	DT
cord-302756-343y63e5	89	73	intravascular	intravascular	JJ
cord-302756-343y63e5	89	74	effector	effector	NN
cord-302756-343y63e5	89	75	of	of	IN
cord-302756-343y63e5	89	76	innate	innate	JJ
cord-302756-343y63e5	89	77	immunity	immunity	NN
cord-302756-343y63e5	89	78	Reincarnation	reincarnation	NN
cord-302756-343y63e5	89	79	of	of	IN
cord-302756-343y63e5	89	80	ancient	ancient	JJ
cord-302756-343y63e5	89	81	links	link	NNS
cord-302756-343y63e5	89	82	between	between	IN
cord-302756-343y63e5	89	83	coagulation	coagulation	NN
cord-302756-343y63e5	89	84	and	and	CC
cord-302756-343y63e5	89	85	complement	complement	VB
cord-302756-343y63e5	89	86	Coagulation	coagulation	NN
cord-302756-343y63e5	89	87	factor	factor	NN
cord-302756-343y63e5	89	88	XII	XII	NNP
cord-302756-343y63e5	89	89	in	in	IN
cord-302756-343y63e5	89	90	thrombosis	thrombosis	NN
cord-302756-343y63e5	89	91	and	and	CC
cord-302756-343y63e5	89	92	inflammation	inflammation	NN
cord-302756-343y63e5	89	93	Platelets	platelet	NNS
cord-302756-343y63e5	89	94	in	in	IN
cord-302756-343y63e5	89	95	inflammation	inflammation	NN
cord-302756-343y63e5	89	96	and	and	CC
cord-302756-343y63e5	89	97	immunity	immunity	NN
cord-302756-343y63e5	89	98	Accepted	Accepted	NNP
cord-302756-343y63e5	89	99	Article	Article	NNP
cord-302756-343y63e5	89	100	This	this	DT
cord-302756-343y63e5	89	101	article	article	NN
cord-302756-343y63e5	89	102	is	be	VBZ
cord-302756-343y63e5	89	103	protected	protect	VBN
cord-302756-343y63e5	89	104	by	by	IN
cord-302756-343y63e5	89	105	copyright	copyright	NN
cord-302756-343y63e5	89	106	.	.	.
cord-302756-343y63e5	90	1	All	all	DT
cord-302756-343y63e5	90	2	rights	right	NNS
cord-302756-343y63e5	90	3	reserved	reserve	VBN
cord-302756-343y63e5	90	4	Hyperinflammatory	Hyperinflammatory	NNP
cord-302756-343y63e5	90	5	shock	shock	NN
cord-302756-343y63e5	90	6	in	in	IN
cord-302756-343y63e5	90	7	children	child	NNS
cord-302756-343y63e5	90	8	during	during	IN
cord-302756-343y63e5	90	9	COVID-19	covid-19	CD
cord-302756-343y63e5	90	10	pandemic	pandemic	NN
cord-302756-343y63e5	90	11	.	.	.
cord-302756-343y63e5	91	1	Lancet	Lancet	NNP
cord-302756-343y63e5	91	2	2020	2020	CD
cord-302756-343y63e5	91	3	.	.	.
cord-302756-343y63e5	92	1	Epub	Epub	NNP
cord-302756-343y63e5	92	2	6	6	CD
cord-302756-343y63e5	92	3	May	May	NNP
cord-302756-343y63e5	92	4	Updates	Updates	NNPS
cord-302756-343y63e5	92	5	in	in	IN
cord-302756-343y63e5	92	6	thrombosis	thrombosis	NN
cord-302756-343y63e5	92	7	in	in	IN
cord-302756-343y63e5	92	8	pediatrics	pediatric	NNS
cord-302756-343y63e5	92	9	:	:	:
cord-302756-343y63e5	93	1	where	where	WRB
cord-302756-343y63e5	93	2	are	be	VBP
cord-302756-343y63e5	93	3	we	-PRON-	PRP
cord-302756-343y63e5	93	4	after	after	IN
cord-302756-343y63e5	93	5	20	20	CD
cord-302756-343y63e5	93	6	years	year	NNS
cord-302756-343y63e5	93	7	?	?	.
cord-302756-343y63e5	94	1	COVID19	covid19	IN
cord-302756-343y63e5	94	2	during	during	IN
cord-302756-343y63e5	94	3	pregnancy	pregnancy	NN
cord-302756-343y63e5	94	4	:	:	:
cord-302756-343y63e5	94	5	a	a	DT
cord-302756-343y63e5	94	6	systematic	systematic	JJ
cord-302756-343y63e5	94	7	review	review	NN
cord-302756-343y63e5	94	8	of	of	IN
cord-302756-343y63e5	94	9	reported	report	VBN
cord-302756-343y63e5	94	10	cases	case	NNS
cord-302756-343y63e5	94	11	COVID-19	covid-19	VBP
cord-302756-343y63e5	94	12	coagulopathy	coagulopathy	NN
cord-302756-343y63e5	94	13	in	in	IN
cord-302756-343y63e5	94	14	caucasian	caucasian	JJ
cord-302756-343y63e5	94	15	patients	patient	NNS
cord-302756-343y63e5	94	16	Bronchoalveolar	Bronchoalveolar	NNP
cord-302756-343y63e5	94	17	hemostasis	hemostasis	NN
cord-302756-343y63e5	94	18	in	in	IN
cord-302756-343y63e5	94	19	lung	lung	NN
cord-302756-343y63e5	94	20	injury	injury	NN
cord-302756-343y63e5	94	21	and	and	CC
cord-302756-343y63e5	94	22	acute	acute	JJ
cord-302756-343y63e5	94	23	respiratory	respiratory	JJ
cord-302756-343y63e5	94	24	distress	distress	NN
cord-302756-343y63e5	94	25	syndrome	syndrome	NN
cord-302756-343y63e5	94	26	Thrombocytopenia	Thrombocytopenia	NNP
cord-302756-343y63e5	94	27	and	and	CC
cord-302756-343y63e5	94	28	its	-PRON-	PRP$
cord-302756-343y63e5	94	29	association	association	NN
cord-302756-343y63e5	94	30	with	with	IN
cord-302756-343y63e5	94	31	mortality	mortality	NN
cord-302756-343y63e5	94	32	in	in	IN
cord-302756-343y63e5	94	33	patients	patient	NNS
cord-302756-343y63e5	94	34	with	with	IN
cord-302756-343y63e5	94	35	COVID-19	COVID-19	NNP
cord-302756-343y63e5	94	36	Causal	Causal	NNP
cord-302756-343y63e5	94	37	relationship	relationship	NN
cord-302756-343y63e5	94	38	between	between	IN
cord-302756-343y63e5	94	39	hyperfibrinogenemia	hyperfibrinogenemia	NN
cord-302756-343y63e5	94	40	,	,	,
cord-302756-343y63e5	94	41	thrombosis	thrombosis	NN
cord-302756-343y63e5	94	42	,	,	,
cord-302756-343y63e5	94	43	and	and	CC
cord-302756-343y63e5	94	44	resistance	resistance	NN
cord-302756-343y63e5	94	45	to	to	IN
cord-302756-343y63e5	94	46	thrombolysis	thrombolysis	NN
cord-302756-343y63e5	94	47	in	in	IN
cord-302756-343y63e5	94	48	mice	mouse	NNS
cord-302756-343y63e5	95	1	Pathological	pathological	JJ
cord-302756-343y63e5	95	2	evidence	evidence	NN
cord-302756-343y63e5	95	3	of	of	IN
cord-302756-343y63e5	95	4	pulmonary	pulmonary	JJ
cord-302756-343y63e5	95	5	thrombotic	thrombotic	JJ
cord-302756-343y63e5	95	6	phenomena	phenomenon	NNS
cord-302756-343y63e5	95	7	in	in	IN
cord-302756-343y63e5	95	8	severe	severe	JJ
cord-302756-343y63e5	95	9	COVID-19	COVID-19	NNP
cord-302756-343y63e5	95	10	COVID-19	COVID-19	NNP
cord-302756-343y63e5	95	11	pneumonia	pneumonia	NN
cord-302756-343y63e5	95	12	:	:	:
cord-302756-343y63e5	95	13	different	different	JJ
cord-302756-343y63e5	95	14	respiratory	respiratory	JJ
cord-302756-343y63e5	95	15	treatments	treatment	NNS
cord-302756-343y63e5	95	16	for	for	IN
cord-302756-343y63e5	95	17	different	different	JJ
cord-302756-343y63e5	95	18	phenotypes	phenotype	NNS
cord-302756-343y63e5	95	19	?	?	.
cord-302756-343y63e5	96	1	ISTH	isth	JJ
cord-302756-343y63e5	96	2	interim	interim	JJ
cord-302756-343y63e5	96	3	guidance	guidance	NN
cord-302756-343y63e5	96	4	on	on	IN
cord-302756-343y63e5	96	5	recognition	recognition	NN
cord-302756-343y63e5	96	6	and	and	CC
cord-302756-343y63e5	96	7	management	management	NN
cord-302756-343y63e5	96	8	of	of	IN
cord-302756-343y63e5	96	9	coagulopathy	coagulopathy	NN
cord-302756-343y63e5	96	10	in	in	IN
cord-302756-343y63e5	96	11	COVID-19	COVID-19	NNP
cord-302756-343y63e5	96	12	COVID-19	COVID-19	NNP
cord-302756-343y63e5	96	13	and	and	CC
cord-302756-343y63e5	96	14	thrombotic	thrombotic	JJ
cord-302756-343y63e5	96	15	or	or	CC
cord-302756-343y63e5	96	16	thromboembolic	thromboembolic	JJ
cord-302756-343y63e5	96	17	disease	disease	NN
cord-302756-343y63e5	96	18	:	:	:
cord-302756-343y63e5	96	19	implications	implication	NNS
cord-302756-343y63e5	96	20	for	for	IN
cord-302756-343y63e5	96	21	prevention	prevention	NN
cord-302756-343y63e5	96	22	,	,	,
cord-302756-343y63e5	96	23	antithrombotic	antithrombotic	JJ
cord-302756-343y63e5	96	24	therapy	therapy	NN
cord-302756-343y63e5	96	25	,	,	,
cord-302756-343y63e5	96	26	and	and	CC
cord-302756-343y63e5	96	27	follow	follow	NN
cord-302756-343y63e5	96	28	-	-	HYPH
cord-302756-343y63e5	96	29	up	up	NN
cord-302756-343y63e5	97	1	The	the	DT
cord-302756-343y63e5	97	2	procoagulant	procoagulant	NN
cord-302756-343y63e5	97	3	pattern	pattern	NN
cord-302756-343y63e5	97	4	if	if	IN
cord-302756-343y63e5	97	5	patients	patient	NNS
cord-302756-343y63e5	97	6	with	with	IN
cord-302756-343y63e5	97	7	COVID-19	covid-19	JJ
cord-302756-343y63e5	97	8	acute	acute	JJ
cord-302756-343y63e5	97	9	respiratory	respiratory	JJ
cord-302756-343y63e5	97	10	distress	distress	NN
cord-302756-343y63e5	97	11	syndrome	syndrome	NN
cord-302756-343y63e5	98	1	Fibrinolytic	fibrinolytic	JJ
cord-302756-343y63e5	98	2	abnormalities	abnormality	NNS
cord-302756-343y63e5	98	3	in	in	IN
cord-302756-343y63e5	98	4	acute	acute	JJ
cord-302756-343y63e5	98	5	respiratory	respiratory	JJ
cord-302756-343y63e5	98	6	distress	distress	NN
cord-302756-343y63e5	98	7	syndrome	syndrome	NN
cord-302756-343y63e5	98	8	(	(	-LRB-
cord-302756-343y63e5	98	9	ARDS	ARDS	NNP
cord-302756-343y63e5	98	10	)	)	-RRB-
cord-302756-343y63e5	98	11	and	and	CC
cord-302756-343y63e5	98	12	versatility	versatility	NN
cord-302756-343y63e5	98	13	of	of	IN
cord-302756-343y63e5	98	14	thrombolytic	thrombolytic	NN
cord-302756-343y63e5	98	15	drugs	drug	NNS
cord-302756-343y63e5	98	16	to	to	TO
cord-302756-343y63e5	98	17	treat	treat	VB
cord-302756-343y63e5	98	18	Accepted	Accepted	NNP
cord-302756-343y63e5	98	19	Article	Article	NNP
cord-302756-343y63e5	98	20	This	this	DT
cord-302756-343y63e5	98	21	article	article	NN
cord-302756-343y63e5	98	22	is	be	VBZ
cord-302756-343y63e5	98	23	protected	protect	VBN
cord-302756-343y63e5	98	24	by	by	IN
cord-302756-343y63e5	98	25	copyright	copyright	NN
cord-302756-343y63e5	98	26	.	.	.
cord-302756-343y63e5	99	1	All	all	DT
cord-302756-343y63e5	99	2	rights	right	NNS
cord-302756-343y63e5	99	3	reserved	reserve	VBD
cord-302756-343y63e5	99	4	COVID-19	COVID-19	NNP
cord-302756-343y63e5	99	5	COVID-19	COVID-19	NNP
cord-302756-343y63e5	99	6	and	and	CC
cord-302756-343y63e5	99	7	what	what	WP
cord-302756-343y63e5	99	8	pediatric	pediatric	JJ
cord-302756-343y63e5	99	9	rheumatologists	rheumatologist	NNS
cord-302756-343y63e5	99	10	should	should	MD
cord-302756-343y63e5	99	11	know	know	VB
cord-302756-343y63e5	99	12	:	:	:
cord-302756-343y63e5	100	1	a	a	DT
cord-302756-343y63e5	100	2	review	review	NN
cord-302756-343y63e5	100	3	from	from	IN
cord-302756-343y63e5	100	4	a	a	DT
cord-302756-343y63e5	100	5	highly	highly	RB
cord-302756-343y63e5	100	6	affected	affected	JJ
cord-302756-343y63e5	100	7	country	country	NN
cord-302756-343y63e5	100	8	Targeting	target	VBG
cord-302756-343y63e5	100	9	complement	complement	JJ
cord-302756-343y63e5	100	10	pathways	pathway	NNS
cord-302756-343y63e5	100	11	in	in	IN
cord-302756-343y63e5	100	12	polytrauma	polytrauma	NN
cord-302756-343y63e5	100	13	-	-	HYPH
cord-302756-343y63e5	100	14	and	and	CC
cord-302756-343y63e5	100	15	sepsis	sepsis	NN
cord-302756-343y63e5	100	16	-	-	HYPH
cord-302756-343y63e5	100	17	induced	induce	VBN
cord-302756-343y63e5	100	18	multiple	multiple	JJ
cord-302756-343y63e5	100	19	-	-	HYPH
cord-302756-343y63e5	100	20	organ	organ	NN
cord-302756-343y63e5	100	21	dysfunction	dysfunction	NN
cord-302756-343y63e5	100	22	Tissue	Tissue	NNP
cord-302756-343y63e5	100	23	plasminogen	plasminogen	NN
cord-302756-343y63e5	100	24	activator	activator	NN
cord-302756-343y63e5	100	25	(	(	-LRB-
cord-302756-343y63e5	100	26	tPA	tPA	NNP
cord-302756-343y63e5	100	27	)	)	-RRB-
cord-302756-343y63e5	100	28	treatment	treatment	NN
cord-302756-343y63e5	100	29	for	for	IN
cord-302756-343y63e5	100	30	COVID-19	covid-19	JJ
cord-302756-343y63e5	100	31	associated	associated	JJ
cord-302756-343y63e5	100	32	acute	acute	JJ
cord-302756-343y63e5	100	33	respiratory	respiratory	JJ
cord-302756-343y63e5	100	34	distress	distress	NN
cord-302756-343y63e5	100	35	syndrome	syndrome	NN
cord-302756-343y63e5	100	36	(	(	-LRB-
cord-302756-343y63e5	100	37	ARDS	ARDS	NNP
cord-302756-343y63e5	100	38	)	)	-RRB-
cord-302756-343y63e5	100	39	:	:	:
cord-302756-343y63e5	100	40	a	a	DT
cord-302756-343y63e5	100	41	case	case	NN
cord-302756-343y63e5	100	42	series	series	NN
cord-302756-343y63e5	100	43	Hypercoaguability	Hypercoaguability	NNP
cord-302756-343y63e5	100	44	of	of	IN
cord-302756-343y63e5	100	45	COVID-19	COVID-19	NNP
cord-302756-343y63e5	100	46	patients	patient	NNS
cord-302756-343y63e5	100	47	in	in	IN
cord-302756-343y63e5	100	48	Intensive	Intensive	NNP
cord-302756-343y63e5	100	49	Care	Care	NNP
cord-302756-343y63e5	100	50	Unit	Unit	NNP
cord-302756-343y63e5	100	51	.	.	.
cord-302756-343y63e5	101	1	A	a	DT
cord-302756-343y63e5	101	2	report	report	NN
cord-302756-343y63e5	101	3	of	of	IN
cord-302756-343y63e5	101	4	thromboelastography	thromboelastography	NNP
cord-302756-343y63e5	101	5	findings	finding	NNS
cord-302756-343y63e5	101	6	and	and	CC
cord-302756-343y63e5	101	7	other	other	JJ
cord-302756-343y63e5	101	8	parameters	parameter	NNS
cord-302756-343y63e5	101	9	of	of	IN
cord-302756-343y63e5	101	10	hemostasis	hemostasis	NN
cord-302756-343y63e5	102	1	COVID-19-related	covid-19-related	JJ
cord-302756-343y63e5	102	2	severe	severe	JJ
cord-302756-343y63e5	102	3	hypercoagulability	hypercoagulability	NN
cord-302756-343y63e5	102	4	in	in	IN
cord-302756-343y63e5	102	5	patients	patient	NNS
cord-302756-343y63e5	102	6	admitted	admit	VBN
cord-302756-343y63e5	102	7	to	to	IN
cord-302756-343y63e5	102	8	intensive	intensive	JJ
cord-302756-343y63e5	102	9	care	care	NN
cord-302756-343y63e5	102	10	unit	unit	NN
cord-302756-343y63e5	102	11	for	for	IN
cord-302756-343y63e5	102	12	acute	acute	JJ
cord-302756-343y63e5	102	13	respiratory	respiratory	JJ
cord-302756-343y63e5	102	14	failure	failure	NN
cord-302756-343y63e5	102	15	.	.	.
cord-302756-343y63e5	103	1	Thrombosis	thrombosis	NN
cord-302756-343y63e5	103	2	and	and	CC
cord-302756-343y63e5	103	3	Haemostasis	Haemostasis	NNP
cord-302756-343y63e5	103	4	2020	2020	CD
cord-302756-343y63e5	103	5	High	high	JJ
cord-302756-343y63e5	103	6	risk	risk	NN
cord-302756-343y63e5	103	7	of	of	IN
cord-302756-343y63e5	103	8	thrombosis	thrombosis	NN
cord-302756-343y63e5	103	9	in	in	IN
cord-302756-343y63e5	103	10	patients	patient	NNS
cord-302756-343y63e5	103	11	with	with	IN
cord-302756-343y63e5	103	12	severe	severe	JJ
cord-302756-343y63e5	103	13	SARS	SARS	NNP
cord-302756-343y63e5	103	14	-	-	HYPH
cord-302756-343y63e5	103	15	CoV-2	CoV-2	NNP
cord-302756-343y63e5	103	16	infection	infection	NN
cord-302756-343y63e5	103	17	:	:	:
cord-302756-343y63e5	103	18	a	a	DT
cord-302756-343y63e5	103	19	multicentre	multicentre	NNP
cord-302756-343y63e5	103	20	prospective	prospective	JJ
cord-302756-343y63e5	103	21	cohort	cohort	NN
cord-302756-343y63e5	103	22	study	study	NN
cord-302756-343y63e5	103	23	.	.	.
cord-302756-343y63e5	104	1	Intensive	Intensive	NNP
cord-302756-343y63e5	104	2	Care	Care	NNP
cord-302756-343y63e5	104	3	Medicine	Medicine	NNP
cord-302756-343y63e5	104	4	2020	2020	CD
cord-302756-343y63e5	104	5	.	.	.
cord-302756-343y63e5	105	1	Epub	Epub	NNP
cord-302756-343y63e5	105	2	4	4	CD
cord-302756-343y63e5	105	3	May	May	NNP
cord-302756-343y63e5	105	4	Endothelial	endothelial	JJ
cord-302756-343y63e5	105	5	cell	cell	NN
cord-302756-343y63e5	105	6	infection	infection	NN
cord-302756-343y63e5	105	7	and	and	CC
cord-302756-343y63e5	105	8	endotheliitis	endotheliitis	NN
cord-302756-343y63e5	105	9	in	in	IN
cord-302756-343y63e5	105	10	COVID-19	COVID-19	NNP
cord-302756-343y63e5	105	11	Biomarkers	Biomarkers	NNPS
cord-302756-343y63e5	105	12	of	of	IN
cord-302756-343y63e5	105	13	endothelial	endothelial	JJ
cord-302756-343y63e5	105	14	activation	activation	NN
cord-302756-343y63e5	105	15	/	/	SYM
cord-302756-343y63e5	105	16	dysfunction	dysfunction	NN
cord-302756-343y63e5	105	17	in	in	IN
cord-302756-343y63e5	105	18	infectious	infectious	JJ
cord-302756-343y63e5	105	19	diseases	disease	NNS
cord-302756-343y63e5	105	20	Clinical	clinical	JJ
cord-302756-343y63e5	105	21	predictors	predictor	NNS
cord-302756-343y63e5	105	22	of	of	IN
cord-302756-343y63e5	105	23	mortality	mortality	NN
cord-302756-343y63e5	105	24	due	due	IN
cord-302756-343y63e5	105	25	to	to	IN
cord-302756-343y63e5	105	26	COVID-19	COVID-19	NNP
cord-302756-343y63e5	105	27	based	base	VBN
cord-302756-343y63e5	105	28	on	on	IN
cord-302756-343y63e5	105	29	analysis	analysis	NN
cord-302756-343y63e5	105	30	of	of	IN
cord-302756-343y63e5	105	31	data	datum	NNS
cord-302756-343y63e5	105	32	of	of	IN
cord-302756-343y63e5	105	33	150	150	CD
cord-302756-343y63e5	105	34	patients	patient	NNS
cord-302756-343y63e5	105	35	from	from	IN
cord-302756-343y63e5	105	36	Wuhan	Wuhan	NNP
cord-302756-343y63e5	105	37	,	,	,
cord-302756-343y63e5	105	38	China	China	NNP
cord-302756-343y63e5	105	39	JT	JT	NNP
cord-302756-343y63e5	105	40	has	have	VBZ
cord-302756-343y63e5	105	41	received	receive	VBN
cord-302756-343y63e5	105	42	honoraria	honorarium	NNS
cord-302756-343y63e5	105	43	from	from	IN
cord-302756-343y63e5	105	44	Bayer	Bayer	NNP
cord-302756-343y63e5	105	45	,	,	,
cord-302756-343y63e5	105	46	BMS	BMS	NNP
cord-302756-343y63e5	105	47	-	-	HYPH
cord-302756-343y63e5	105	48	Pfizer	Pfizer	NNP
cord-302756-343y63e5	105	49	,	,	,
cord-302756-343y63e5	105	50	Daichii	Daichii	NNP
cord-302756-343y63e5	105	51	-	-	HYPH
cord-302756-343y63e5	105	52	Sankyo	Sankyo	NNP
cord-302756-343y63e5	105	53	,	,	,
cord-302756-343y63e5	105	54	Boehringer	Boehringer	NNP
cord-302756-343y63e5	105	55	,	,	,
cord-302756-343y63e5	105	56	Mitsubishi	Mitsubishi	NNP
cord-302756-343y63e5	105	57	,	,	,
cord-302756-343y63e5	105	58	Novo	Novo	NNP
cord-302756-343y63e5	105	59	Nordisk	Nordisk	NNP
cord-302756-343y63e5	105	60	,	,	,
cord-302756-343y63e5	105	61	Octapharma	Octapharma	NNP
cord-302756-343y63e5	105	62	,	,	,
cord-302756-343y63e5	105	63	Amgen	Amgen	NNP
cord-302756-343y63e5	105	64	,	,	,
cord-302756-343y63e5	105	65	Norgine	Norgine	NNP
cord-302756-343y63e5	105	66	,	,	,
cord-302756-343y63e5	105	67	Alexion	Alexion	NNP
cord-302756-343y63e5	105	68	,	,	,
cord-302756-343y63e5	105	69	Sobi	Sobi	NNP
cord-302756-343y63e5	105	70	,	,	,
cord-302756-343y63e5	105	71	CSL	CSL	NNP
cord-302756-343y63e5	105	72	-	-	HYPH
cord-302756-343y63e5	105	73	Behring	Behring	NNP
cord-302756-343y63e5	105	74	and	and	CC
cord-302756-343y63e5	105	75	Roche	Roche	NNP
cord-302756-343y63e5	105	76	-	-	HYPH
cord-302756-343y63e5	105	77	Chugai	Chugai	NNP
cord-302756-343y63e5	105	78	,	,	,
cord-302756-343y63e5	105	79	none	none	NN
cord-302756-343y63e5	105	80	of	of	IN
cord-302756-343y63e5	105	81	which	which	WDT
cord-302756-343y63e5	105	82	were	be	VBD
cord-302756-343y63e5	105	83	involved	involve	VBN
cord-302756-343y63e5	105	84	in	in	IN
cord-302756-343y63e5	105	85	this	this	DT
cord-302756-343y63e5	105	86	editorial	editorial	NN
cord-302756-343y63e5	105	87	.	.	.
cord-302756-343y63e5	106	1	SA	SA	NNP
cord-302756-343y63e5	106	2	is	be	VBZ
cord-302756-343y63e5	106	3	an	an	DT
cord-302756-343y63e5	106	4	editor	editor	NN
cord-302756-343y63e5	106	5	of	of	IN
cord-302756-343y63e5	106	6	Anaesthesia	Anaesthesia	NNP
cord-302756-343y63e5	106	7	.	.	.
cord-302756-343y63e5	107	1	She	-PRON-	PRP
cord-302756-343y63e5	107	2	has	have	VBZ
cord-302756-343y63e5	107	3	received	receive	VBN
cord-302756-343y63e5	107	4	research	research	NN
cord-302756-343y63e5	107	5	funding	funding	NN
cord-302756-343y63e5	107	6	and	and	CC
cord-302756-343y63e5	107	7	honoraria	honoraria	NN
cord-302756-343y63e5	107	8	from	from	IN
cord-302756-343y63e5	107	9	Haemonetics	Haemonetics	NNP
cord-302756-343y63e5	107	10	,	,	,
cord-302756-343y63e5	107	11	Pharmacosmos	Pharmacosmos	NNP
cord-302756-343y63e5	107	12	,	,	,
cord-302756-343y63e5	107	13	Octapharma	Octapharma	NNP
cord-302756-343y63e5	107	14	,	,	,
cord-302756-343y63e5	107	15	CSL	CSL	NNP
cord-302756-343y63e5	107	16	Behring	Behring	NNP
cord-302756-343y63e5	107	17	,	,	,
cord-302756-343y63e5	107	18	and	and	CC
cord-302756-343y63e5	107	19	Nordic	Nordic	NNP
cord-302756-343y63e5	107	20	Pharma	Pharma	NNP
cord-302756-343y63e5	107	21	,	,	,
cord-302756-343y63e5	107	22	none	none	NN
cord-302756-343y63e5	107	23	of	of	IN
cord-302756-343y63e5	107	24	which	which	WDT
cord-302756-343y63e5	107	25	were	be	VBD
cord-302756-343y63e5	107	26	involved	involve	VBN
cord-302756-343y63e5	107	27	in	in	IN
cord-302756-343y63e5	107	28	this	this	DT
cord-302756-343y63e5	107	29	editorial	editorial	NN
cord-302756-343y63e5	107	30	.	.	.
cord-302756-343y63e5	108	1	No	no	DT
cord-302756-343y63e5	108	2	other	other	JJ
cord-302756-343y63e5	108	3	competing	compete	VBG
cord-302756-343y63e5	108	4	interests	interest	NNS
cord-302756-343y63e5	108	5	declared	declare	VBD
cord-302756-343y63e5	108	6	.	.	.
cord-302756-343y63e5	109	1	This	this	DT
cord-302756-343y63e5	109	2	article	article	NN
cord-302756-343y63e5	109	3	is	be	VBZ
cord-302756-343y63e5	109	4	protected	protect	VBN
cord-302756-343y63e5	109	5	by	by	IN
cord-302756-343y63e5	109	6	copyright	copyright	NN
cord-302756-343y63e5	109	7	.	.	.
cord-302756-343y63e5	110	1	All	all	DT
cord-302756-343y63e5	110	2	rights	right	NNS
cord-302756-343y63e5	110	3	reserved	reserve	VBD
cord-302756-343y63e5	110	4	This	this	DT
cord-302756-343y63e5	110	5	article	article	NN
cord-302756-343y63e5	110	6	is	be	VBZ
cord-302756-343y63e5	110	7	protected	protect	VBN
cord-302756-343y63e5	110	8	by	by	IN
cord-302756-343y63e5	110	9	copyright	copyright	NN
cord-302756-343y63e5	110	10	.	.	.
cord-302756-343y63e5	111	1	All	all	DT
cord-302756-343y63e5	111	2	rights	right	NNS
cord-302756-343y63e5	111	3	reserved	reserve	VBN
cord-302756-343y63e5	111	4	 	 	_SP